{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:37:31Z","timestamp":1795034251521,"version":"4.10.2"},"reference-count":544,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Project of Shanghai Mental Health Center","id":[{"id":"https:\/\/ror.org\/05bd2wa15","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203445"],"award-info":[{"award-number":["82203445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273293"],"award-info":[{"award-number":["82273293"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u201cPhoenix Introduction Plan\u201d Talent Startover Project of Tangdu Hospital, Fourth Military Medical Universit","id":[{"id":"https:\/\/ror.org\/00ms48f15","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Health Commission Health Industry Clinical Research Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Regulatory T cells (Treg cells or Tregs), a subset of CD4\u207a T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function\u2014whether deficiency or hyperactivity\u2014is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.<\/jats:p>","DOI":"10.1038\/s41392-025-02326-4","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:46:06Z","timestamp":1760453166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":186,"title":["Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential"],"prefix":"10.1038","volume":"10","author":[{"given":"Lingling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3243-085X","authenticated-orcid":false,"given":"Dongen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-3388","authenticated-orcid":false,"given":"Yun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"2326_CR1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.it.2019.08.003","volume":"40","author":"DA Horwitz","year":"2019","unstructured":"Horwitz, D. A., Fahmy, T. M., Piccirillo, C. A. & La Cava, A. Rebalancing immune homeostasis to treat autoimmune diseases. Trends Immunol. 40, 888\u2013908 (2019).","journal-title":"Trends Immunol."},{"key":"2326_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330\u2013336 (2003).","journal-title":"Nat. Immunol."},{"key":"2326_CR3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057\u20131061 (2003).","journal-title":"Science"},{"key":"2326_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.immuni.2024.07.010","volume":"57","author":"K Ichiyama","year":"2024","unstructured":"Ichiyama, K. et al. Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity. Immunity 57, 2043\u20132060.e2010 (2024).","journal-title":"Immunity"},{"key":"2326_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531\u2013562 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"2326_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1146\/annurev.immunol.18.1.423","volume":"18","author":"EM Shevach","year":"2000","unstructured":"Shevach, E. M. Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol. 18, 423\u2013449 (2000).","journal-title":"Annu. Rev. Immunol."},{"key":"2326_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12170","volume":"259","author":"KS Smigiel","year":"2014","unstructured":"Smigiel, K. S., Srivastava, S., Stolley, J. M. & Campbell, D. J. Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol. Rev. 259, 40\u201359 (2014).","journal-title":"Immunol. Rev."},{"key":"2326_CR8","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.4049\/jimmunol.1003099","volume":"186","author":"SA McClymont","year":"2011","unstructured":"McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918\u20133926 (2011).","journal-title":"J. Immunol."},{"key":"2326_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","volume":"140","author":"DR Littman","year":"2010","unstructured":"Littman, D. R. & Rudensky, A. Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845\u2013858 (2010).","journal-title":"Cell"},{"key":"2326_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molmed.2016.07.003","volume":"22","author":"IR Kasper","year":"2016","unstructured":"Kasper, I. R., Apostolidis, S. A., Sharabi, A. & Tsokos, G. C. Empowering regulatory T cells in autoimmunity. Trends Mol. Med. 22, 784\u2013797 (2016).","journal-title":"Trends Mol. Med."},{"key":"2326_CR11","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/eji.201646739","volume":"47","author":"M Becker","year":"2017","unstructured":"Becker, M., Levings, M. K. & Daniel, C. Adipose-tissue regulatory T cells: critical players in adipose-immune crosstalk. Eur. J. Immunol. 47, 1867\u20131874 (2017).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274199","volume":"14","author":"R Alfar","year":"2023","unstructured":"Alfar, R. et al. Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth. Front. Immunol. 14, 1274199 (2023).","journal-title":"Front. Immunol."},{"key":"2326_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-023-01504-2","volume":"24","author":"A Glasner","year":"2023","unstructured":"Glasner, A. et al. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. Nat. Immunol. 24, 1020\u20131035 (2023).","journal-title":"Nat. Immunol."},{"key":"2326_CR14","doi-asserted-by":"publisher","first-page":"1308264","DOI":"10.3389\/fimmu.2023.1308264","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang, Y. et al. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors. Front. Immunol. 14, 1308264 (2023).","journal-title":"Front. Immunol."},{"key":"2326_CR15","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ijc.34281","volume":"152","author":"Y Peng","year":"2023","unstructured":"Peng, Y. et al. CD25: a potential tumor therapeutic target. Int. J. Cancer 152, 1290\u20131303 (2023).","journal-title":"Int. J. Cancer"},{"key":"2326_CR16","doi-asserted-by":"publisher","first-page":"110358","DOI":"10.1016\/j.intimp.2023.110358","volume":"120","author":"J Zhao","year":"2023","unstructured":"Zhao, J. et al. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer. Int. Immunopharmacol. 120, 110358 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2326_CR17","doi-asserted-by":"crossref","unstructured":"Tobin, J. W. D., Bednarska, K., Campbell, A. & Keane, C. PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma. Cells. 10, 1152 (2021).","DOI":"10.3390\/cells10051152"},{"key":"2326_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","volume":"37","author":"DT Harris","year":"2016","unstructured":"Harris, D. T. & Kranz, D. M. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharm. Sci. 37, 220\u2013230 (2016).","journal-title":"Trends Pharm. Sci."},{"key":"2326_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","volume":"395","author":"B Sawitzki","year":"2020","unstructured":"Sawitzki, B. et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials. Lancet 395, 1627\u20131639 (2020).","journal-title":"Lancet"},{"key":"2326_CR20","doi-asserted-by":"publisher","first-page":"m3734","DOI":"10.1136\/bmj.m3734","volume":"371","author":"A Roemhild","year":"2020","unstructured":"Roemhild, A. et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial. BMJ 371, m3734 (2020).","journal-title":"BMJ"},{"key":"2326_CR21","doi-asserted-by":"publisher","first-page":"108409","DOI":"10.1016\/j.intimp.2021.108409","volume":"102","author":"SA Beheshti","year":"2022","unstructured":"Beheshti, S. A., Shamsasenjan, K., Ahmadi, M. & Abbasi, B. C. A. R. Treg: a new approach in the treatment of autoimmune diseases. Int. Immunopharmacol. 102, 108409 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"2326_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald, K. G. et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Investig. 126, 1413\u20131424 (2016).","journal-title":"J. Clin. Investig."},{"key":"2326_CR23","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2326_CR24","doi-asserted-by":"crossref","unstructured":"Dong, S. et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 6, e147474 (2021).","DOI":"10.1172\/jci.insight.147474"},{"key":"2326_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1182\/bloodadvances.2020003219","volume":"5","author":"ML MacMillan","year":"2021","unstructured":"MacMillan, M. L. et al. First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Adv. 5, 1425\u20131436 (2021).","journal-title":"Blood Adv."},{"key":"2326_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","volume":"5","author":"A Pierini","year":"2021","unstructured":"Pierini, A. et al. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 5, 1199\u20131208 (2021).","journal-title":"Blood Adv."},{"key":"2326_CR27","first-page":"723","volume":"18","author":"RK Gershon","year":"1970","unstructured":"Gershon, R. K. & Kondo, K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18, 723\u2013737 (1970).","journal-title":"Immunology"},{"key":"2326_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/250594a0","volume":"250","author":"RK Gershon","year":"1974","unstructured":"Gershon, R. K., Mokyr, M. B. & Mitchell, M. S. Activation of suppressor T cells by tumour cells and specific antibody. Nature 250, 594\u2013596 (1974).","journal-title":"Nature"},{"key":"2326_CR29","first-page":"903","volume":"21","author":"RK Gershon","year":"1971","unstructured":"Gershon, R. K. & Kondo, K. Infectious immunological tolerance. Immunology 21, 903\u2013914 (1971).","journal-title":"Immunology"},{"key":"2326_CR30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi, S. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151\u20131164 (1995).","journal-title":"J. Immunol."},{"key":"2326_CR31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","volume":"167","author":"C Baecher-Allan","year":"2001","unstructured":"Baecher-Allan, C., Brown, J. A., Freeman, G. J. & Hafler, D. A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167, 1245\u20131253 (2001).","journal-title":"J. Immunol."},{"key":"2326_CR32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.193.11.1303","volume":"193","author":"D Dieckmann","year":"2001","unstructured":"Dieckmann, D. et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 193, 1303\u20131310 (2001).","journal-title":"J. Exp. Med."},{"key":"2326_CR33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1084\/jem.193.11.1285","volume":"193","author":"H Jonuleit","year":"2001","unstructured":"Jonuleit, H. et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193, 1285\u20131294 (2001).","journal-title":"J. Exp. Med."},{"key":"2326_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ni909","volume":"4","author":"R Khattri","year":"2003","unstructured":"Khattri, R., Cox, T., Yasayko, S. A. & Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337\u2013342 (2003).","journal-title":"Nat. Immunol."},{"key":"2326_CR35","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/intimm\/dxh165","volume":"16","author":"H Yagi","year":"2004","unstructured":"Yagi, H. et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int. Immunol. 16, 1643\u20131656 (2004).","journal-title":"Int. Immunol."},{"key":"2326_CR36","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/eji.200526189","volume":"35","author":"G Roncador","year":"2005","unstructured":"Roncador, G. et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur. J. Immunol. 35, 1681\u20131691 (2005).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR37","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","volume":"198","author":"W Chen","year":"2003","unstructured":"Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875\u20131886 (2003).","journal-title":"J. Exp. Med."},{"key":"2326_CR38","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.4049\/jimmunol.176.2.1266","volume":"176","author":"A Trenado","year":"2006","unstructured":"Trenado, A. et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation\/differentiation of pathogenic T cells. J. Immunol. 176, 1266\u20131273 (2006).","journal-title":"J. Immunol."},{"key":"2326_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/cei.12415","volume":"178","author":"H Tanaka","year":"2014","unstructured":"Tanaka, H. et al. Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells. Clin. Exp. Immunol. 178, 253\u2013261 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"2326_CR40","doi-asserted-by":"publisher","first-page":"83ra42","DOI":"10.1126\/scitranslmed.3002076","volume":"3","author":"P Sagoo","year":"2011","unstructured":"Sagoo, P. et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 3, 83ra42 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2326_CR41","doi-asserted-by":"crossref","unstructured":"Ahmadzadeh, M. et al. Tumor-infiltrating human CD4(+) regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci Immunol. 4, eaao4310 (2019).","DOI":"10.1126\/sciimmunol.aao4310"},{"key":"2326_CR42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito, T. et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679\u2013684 (2016).","journal-title":"Nat. Med."},{"key":"2326_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13024-023-00692-7","volume":"18","author":"P Yeapuri","year":"2023","unstructured":"Yeapuri, P. et al. Amyloid-\u03b2 specific regulatory T cells attenuate Alzheimer\u2019s disease pathobiology in APP\/PS1 mice. Mol. Neurodegener. 18, 97 (2023).","journal-title":"Mol. Neurodegener."},{"key":"2326_CR44","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.7150\/thno.75965","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. Adoptive therapy with amyloid-\u03b2 specific regulatory T cells alleviates Alzheimer\u2019s disease. Theranostics 12, 7668\u20137680 (2022).","journal-title":"Theranostics"},{"key":"2326_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","volume":"133","author":"P Trzonkowski","year":"2009","unstructured":"Trzonkowski, P. et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 133, 22\u201326 (2009).","journal-title":"Clin. Immunol."},{"key":"2326_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.coi.2011.06.006","volume":"23","author":"M Edinger","year":"2011","unstructured":"Edinger, M. & Hoffmann, P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr. Opin. Immunol. 23, 679\u2013684 (2011).","journal-title":"Curr. Opin. Immunol."},{"key":"2326_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","volume":"153","author":"N Marek-Trzonkowska","year":"2014","unstructured":"Marek-Trzonkowska, N. et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets\u2014results of one year follow-up. Clin. Immunol. 153, 23\u201330 (2014).","journal-title":"Clin. Immunol."},{"key":"2326_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcancer.2005.11.005","volume":"16","author":"T Yamaguchi","year":"2006","unstructured":"Yamaguchi, T. & Sakaguchi, S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 16, 115\u2013123 (2006).","journal-title":"Semin Cancer Biol."},{"key":"2326_CR49","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant, D. V. et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol. 20, 724\u2013735 (2019).","journal-title":"Nat. Immunol."},{"key":"2326_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41590-024-01746-8","volume":"25","author":"X Long","year":"2024","unstructured":"Long, X. et al. Targeting JMJD1C to selectively disrupt tumor T(reg) cell fitness enhances antitumor immunity. Nat. Immunol. 25, 525\u2013536 (2024).","journal-title":"Nat. Immunol."},{"key":"2326_CR51","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41590-024-01912-y","volume":"25","author":"P Nie","year":"2024","unstructured":"Nie, P. et al. Targeting p97-Npl4 interaction inhibits tumor T(reg) cell development to enhance tumor immunity. Nat. Immunol. 25, 1623\u20131636 (2024).","journal-title":"Nat. Immunol."},{"key":"2326_CR52","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.stem.2023.04.002","volume":"30","author":"NJ Hogrebe","year":"2023","unstructured":"Hogrebe, N. J., Ishahak, M. & Millman, J. R. Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell 30, 530\u2013548 (2023).","journal-title":"Cell Stem Cell"},{"key":"2326_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12160","volume":"259","author":"EM Shevach","year":"2014","unstructured":"Shevach, E. M. & Thornton, A. M. tTregs, pTregs, and iTregs: similarities and differences. Immunol. Rev. 259, 88\u2013102 (2014).","journal-title":"Immunol. Rev."},{"key":"2326_CR54","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.4049\/jimmunol.0904028","volume":"184","author":"AM Thornton","year":"2010","unstructured":"Thornton, A. M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184, 3433\u20133441 (2010).","journal-title":"J. Immunol."},{"key":"2326_CR55","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20120914","volume":"209","author":"JM Weiss","year":"2012","unstructured":"Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J. Exp. Med. 209, 1723\u20131742 (2012). s1721.","journal-title":"J. Exp. Med."},{"key":"2326_CR56","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1084\/jem.20120822","volume":"209","author":"M Yadav","year":"2012","unstructured":"Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209, 1713\u20131722 (2012).","journal-title":"J. Exp. Med."},{"key":"2326_CR57","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.4049\/jimmunol.1901250","volume":"204","author":"R Opstelten","year":"2020","unstructured":"Opstelten, R. et al. GPA33: a marker to identify stable human regulatory T cells. J. Immunol. 204, 3139\u20133148 (2020).","journal-title":"J. Immunol."},{"key":"2326_CR58","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nature08750","volume":"463","author":"Y Zheng","year":"2010","unstructured":"Zheng, Y. et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463, 808\u2013812 (2010).","journal-title":"Nature"},{"key":"2326_CR59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/imr.12173","volume":"259","author":"DV Sawant","year":"2014","unstructured":"Sawant, D. V. & Vignali, D. A. Once a Treg, always a Treg?. Immunol. Rev. 259, 173\u2013191 (2014).","journal-title":"Immunol. Rev."},{"key":"2326_CR60","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1182\/blood-2005-06-2403","volume":"107","author":"N Seddiki","year":"2006","unstructured":"Seddiki, N. et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 107, 2830\u20132838 (2006).","journal-title":"Blood"},{"key":"2326_CR61","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.4049\/jimmunol.0903781","volume":"184","author":"NJ Booth","year":"2010","unstructured":"Booth, N. J. et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J. Immunol. 184, 4317\u20134326 (2010).","journal-title":"J. Immunol."},{"key":"2326_CR62","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899\u2013911 (2009).","journal-title":"Immunity"},{"key":"2326_CR63","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.immuni.2008.03.018","volume":"28","author":"T Ito","year":"2008","unstructured":"Ito, T. et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28, 870\u2013880 (2008).","journal-title":"Immunity"},{"key":"2326_CR64","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/eji.201445269","volume":"45","author":"AS Bergot","year":"2015","unstructured":"Bergot, A. S. et al. TCR sequences and tissue distribution discriminate the subsets of na\u00efve and activated\/memory Treg cells in mice. Eur. J. Immunol. 45, 1524\u20131534 (2015).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR65","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.20031562","volume":"199","author":"J Huehn","year":"2004","unstructured":"Huehn, J. et al. Developmental stage, phenotype, and migration distinguish naive- and effector\/memory-like CD4+ regulatory T cells. J. Exp. Med. 199, 303\u2013313 (2004).","journal-title":"J. Exp. Med."},{"key":"2326_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/cmi.2015.49","volume":"12","author":"ZQ Hu","year":"2015","unstructured":"Hu, Z. Q. & Zhao, W. H. The IL-33\/ST2 axis is specifically required for development of adipose tissue-resident regulatory T cells. Cell. Mol. Immunol. 12, 521\u2013524 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"2326_CR67","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.4049\/jimmunol.1500020","volume":"194","author":"JM Han","year":"2015","unstructured":"Han, J. M. et al. IL-33 Reverses an obesity-induced deficit in visceral adipose tissue ST2+ T regulatory cells and ameliorates adipose tissue inflammation and insulin resistance. J. Immunol. 194, 4777\u20134783 (2015).","journal-title":"J. Immunol."},{"key":"2326_CR68","doi-asserted-by":"publisher","first-page":"600973","DOI":"10.3389\/fimmu.2020.600973","volume":"11","author":"C Cosovanu","year":"2020","unstructured":"Cosovanu, C. & Neumann, C. The many functions of Foxp3(+) regulatory T cells in the intestine. Front. Immunol. 11, 600973 (2020).","journal-title":"Front. Immunol."},{"key":"2326_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/mi.2015.74","volume":"9","author":"BH Yang","year":"2016","unstructured":"Yang, B. H. et al. Foxp3(+) T cells expressing ROR\u03b3t represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol. 9, 444\u2013457 (2016).","journal-title":"Mucosal Immunol."},{"key":"2326_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang, A. et al. Regulatory T cells in immune checkpoint blockade antitumor therapy. Mol. Cancer 23, 251 (2024).","journal-title":"Mol. Cancer"},{"key":"2326_CR71","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4110\/in.2020.20.e4","volume":"20","author":"JH Kim","year":"2020","unstructured":"Kim, J. H., Kim, B. S. & Lee, S. K. Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy. Immune Netw. 20, e4 (2020).","journal-title":"Immune Netw."},{"key":"2326_CR72","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.immuni.2012.03.018","volume":"36","author":"J Seneschal","year":"2012","unstructured":"Seneschal, J. et al. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36, 873\u2013884 (2012).","journal-title":"Immunity"},{"key":"2326_CR73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41392-024-02050-5","volume":"10","author":"J Li","year":"2025","unstructured":"Li, J., Xiao, C., Li, C. & He, J. Tissue-resident immune cells: from defining characteristics to roles in diseases. Signal Transduct. Target. Ther. 10, 12 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2326_CR74","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41590-022-01208-z","volume":"23","author":"L Yshii","year":"2022","unstructured":"Yshii, L. et al. Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation. Nat. Immunol. 23, 878\u2013891 (2022).","journal-title":"Nat. Immunol."},{"key":"2326_CR75","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41590-018-0051-0","volume":"19","author":"D Zemmour","year":"2018","unstructured":"Zemmour, D. et al. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat. Immunol. 19, 291\u2013301 (2018).","journal-title":"Nat. Immunol."},{"key":"2326_CR76","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.immuni.2019.01.001","volume":"50","author":"RJ Miragaia","year":"2019","unstructured":"Miragaia, R. J. et al. Single-cell transcriptomics of regulatory T cells reveals trajectories of tissue adaptation. Immunity 50, 493\u2013504 e497 (2019).","journal-title":"Immunity"},{"key":"2326_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24213-6","volume":"12","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human T(reg) compartment. Nat. Commun. 12, 3913 (2021).","journal-title":"Nat. Commun."},{"key":"2326_CR78","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293\u20131308.e1236 (2018).","journal-title":"Cell"},{"key":"2326_CR79","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.clim.2004.04.003","volume":"112","author":"P Trzonkowski","year":"2004","unstructured":"Trzonkowski, P. et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 112, 258\u2013267 (2004).","journal-title":"Clin. Immunol."},{"key":"2326_CR80","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","volume":"12","author":"Z Li","year":"2015","unstructured":"Li, Z., Li, D., Tsun, A. & Li, B. FOXP3+ regulatory T cells and their functional regulation. Cell. Mol. Immunol. 12, 558\u2013565 (2015).","journal-title":"Cell. Mol. Immunol."},{"key":"2326_CR81","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1101\/gad.12.6.782","volume":"12","author":"K Hahm","year":"1998","unstructured":"Hahm, K. et al. Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev. 12, 782\u2013796 (1998).","journal-title":"Genes Dev."},{"key":"2326_CR82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/eji.201847935","volume":"49","author":"AM Thornton","year":"2019","unstructured":"Thornton, A. M. et al. Helios(+) and Helios(-) Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires. Eur. J. Immunol. 49, 398\u2013412 (2019).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR83","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon, I. et al. CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat. Cancer 1, 1153\u20131166 (2020).","journal-title":"Nat. Cancer"},{"key":"2326_CR84","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257\u20131265 (2007).","journal-title":"J. Exp. Med."},{"key":"2326_CR85","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.4049\/jimmunol.177.10.6780","volume":"177","author":"JJ Kobie","year":"2006","unstructured":"Kobie, J. J. et al. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5\u2019-adenosine monophosphate to adenosine. J. Immunol. 177, 6780\u20136786 (2006).","journal-title":"J. Immunol."},{"key":"2326_CR86","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1016\/j.febslet.2015.07.027","volume":"589","author":"MR Bono","year":"2015","unstructured":"Bono, M. R. et al. CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett. 589, 3454\u20133460 (2015).","journal-title":"FEBS Lett."},{"key":"2326_CR87","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1084\/jem.180.6.2401","volume":"180","author":"LM Bradley","year":"1994","unstructured":"Bradley, L. M., Watson, S. R. & Swain, S. L. Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J. Exp. Med. 180, 2401\u20132406 (1994).","journal-title":"J. Exp. Med."},{"key":"2326_CR88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/304030a0","volume":"304","author":"WM Gallatin","year":"1983","unstructured":"Gallatin, W. M., Weissman, I. L. & Butcher, E. C. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 304, 30\u201334 (1983).","journal-title":"Nature"},{"key":"2326_CR89","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4049\/jimmunol.178.1.291","volume":"178","author":"GM Venturi","year":"2007","unstructured":"Venturi, G. M., Conway, R. M., Steeber, D. A. & Tedder, T. F. CD25+CD4+ regulatory T cell migration requires L-selectin expression: L-selectin transcriptional regulation balances constitutive receptor turnover. J. Immunol. 178, 291\u2013300 (2007).","journal-title":"J. Immunol."},{"key":"2326_CR90","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.4049\/jimmunol.174.9.5444","volume":"174","author":"I Suffia","year":"2005","unstructured":"Suffia, I., Reckling, S. K., Salay, G. & Belkaid, Y. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J. Immunol. 174, 5444\u20135455 (2005).","journal-title":"J. Immunol."},{"key":"2326_CR91","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","volume":"29","author":"WL Redmond","year":"2009","unstructured":"Redmond, W. L., Ruby, C. E. & Weinberg, A. D. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29, 187\u2013201 (2009).","journal-title":"Crit. Rev. Immunol."},{"key":"2326_CR92","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ijc.24435","volume":"125","author":"N Kitamura","year":"2009","unstructured":"Kitamura, N. et al. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int. J. Cancer 125, 630\u2013638 (2009).","journal-title":"Int. J. Cancer"},{"key":"2326_CR93","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2007.04.017","volume":"27","author":"T Yamaguchi","year":"2007","unstructured":"Yamaguchi, T. et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27, 145\u2013159 (2007).","journal-title":"Immunity"},{"key":"2326_CR94","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2172-13-30","volume":"13","author":"Y Tian","year":"2012","unstructured":"Tian, Y. et al. A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. BMC Immunol. 13, 30 (2012).","journal-title":"BMC Immunol."},{"key":"2326_CR95","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/jid.2009.313","volume":"130","author":"S Klein","year":"2010","unstructured":"Klein, S., Kretz, C. C., Krammer, P. H. & Kuhn, A. CD127(low\/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J. Investig. Dermatol. 130, 492\u2013499 (2010).","journal-title":"J. Investig. Dermatol."},{"key":"2326_CR96","doi-asserted-by":"publisher","first-page":"712","DOI":"10.7150\/ijms.44088","volume":"17","author":"W Zhou","year":"2020","unstructured":"Zhou, W. et al. Expression of CD4+CD25+CD127(Low) regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma. Int J. Med. Sci. 17, 712\u2013719 (2020).","journal-title":"Int J. Med. Sci."},{"key":"2326_CR97","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/art.24181","volume":"60","author":"P Kolar","year":"2009","unstructured":"Kolar, P. et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum. 60, 123\u2013132 (2009).","journal-title":"Arthritis Rheum."},{"key":"2326_CR98","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 38, 255 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2326_CR99","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/eji.202048747","volume":"51","author":"ZN Willsmore","year":"2021","unstructured":"Willsmore, Z. N. et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur. J. Immunol. 51, 544\u2013556 (2021).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22885-8","volume":"12","author":"Z Amoozgar","year":"2021","unstructured":"Amoozgar, Z. et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat. Commun. 12, 2582 (2021).","journal-title":"Nat. Commun."},{"key":"2326_CR101","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller, N., Anderson, A. C. & Kuchroo, V. K. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity 57, 206\u2013222 (2024).","journal-title":"Immunity"},{"key":"2326_CR102","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-023-01503-8","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L. et al. Correction: targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16, 105 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2326_CR103","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/2326-6066.CIR-18-0066","volume":"6","author":"AE Overacre-Delgoffe","year":"2018","unstructured":"Overacre-Delgoffe, A. E. & Vignali, D. A. A. Treg fragility: a prerequisite for effective antitumor immunity?. Cancer Immunol. Res. 6, 882\u2013887 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR104","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/imr.12175","volume":"259","author":"S Hori","year":"2014","unstructured":"Hori, S. Lineage stability and phenotypic plasticity of Foxp3(+) regulatory T cells. Immunol. Rev. 259, 159\u2013172 (2014).","journal-title":"Immunol. Rev."},{"key":"2326_CR105","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nri3464","volume":"13","author":"S Sakaguchi","year":"2013","unstructured":"Sakaguchi, S. et al. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13, 461\u2013467 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"2326_CR106","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3389\/fimmu.2019.02716","volume":"10","author":"H Shi","year":"2019","unstructured":"Shi, H. & Chi, H. Metabolic control of treg cell stability, plasticity, and tissue-specific heterogeneity. Front. Immunol. 10, 2716 (2019).","journal-title":"Front. Immunol."},{"key":"2326_CR107","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"JH Kang","year":"2023","unstructured":"Kang, J. H. & Zappasodi, R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer 9, 911\u2013927 (2023).","journal-title":"Trends Cancer"},{"key":"2326_CR108","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson, M. J. et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591, 645\u2013651 (2021).","journal-title":"Nature"},{"key":"2326_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110986","volume":"39","author":"J Gu","year":"2022","unstructured":"Gu, J. et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-beta signaling in regulatory T cells. Cell Rep. 39, 110986 (2022).","journal-title":"Cell Rep."},{"key":"2326_CR110","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev-immunol-020711-075058","volume":"30","author":"Y Kanno","year":"2012","unstructured":"Kanno, Y. et al. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu. Rev. Immunol. 30, 707\u2013731 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"2326_CR111","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1111\/ajt.15845","volume":"20","author":"SQ Chen","year":"2020","unstructured":"Chen, S. Q. et al. Epigenetically modifying the locus for generation of stable antigen-specific Tregs as cellular therapeutics. Am. J. Transpl. 20, 2366\u20132379 (2020).","journal-title":"Am. J. Transpl."},{"key":"2326_CR112","doi-asserted-by":"crossref","unstructured":"von Knethen, A. et al. Histone deacetylation inhibitors as modulators of regulatory T cells. Int. J. Mol. Sci. 21, 2356 (2020).","DOI":"10.3390\/ijms21072356"},{"key":"2326_CR113","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2014.07.030","volume":"158","author":"X Li","year":"2014","unstructured":"Li, X. et al. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell 158, 734\u2013748 (2014).","journal-title":"Cell"},{"key":"2326_CR114","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41577-023-00893-7","volume":"23","author":"JL Trujillo-Ochoa","year":"2023","unstructured":"Trujillo-Ochoa, J. L., Kazemian, M. & Afzali, B. The role of transcription factors in shaping regulatory T cell identity. Nat. Rev. Immunol. 23, 842\u2013856 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2326_CR115","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41422-020-0324-7","volume":"30","author":"N Ohkura","year":"2020","unstructured":"Ohkura, N. & Sakaguchi, S. Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases. Cell Res. 30, 465\u2013474 (2020).","journal-title":"Cell Res."},{"key":"2326_CR116","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4049\/jimmunol.2300184","volume":"211","author":"ME Medof","year":"2023","unstructured":"Medof, M. E., Rieder, S. A. & Shevach, E. M. Disabled C3ar1\/C5ar1 signaling in Foxp3 T regulatory cells leads to TSDR demethylation and long-term stability. J. Immunol. 211, 1359\u20131366 (2023).","journal-title":"J. Immunol."},{"key":"2326_CR117","doi-asserted-by":"crossref","unstructured":"Pokhrel, R. H., Kang, B., Timilshina, M. & Chang, J. H. AMPK amplifies IL2-STAT5 signaling to maintain stability of regulatory T cells in aged mice. Int. J. Mol. Sci. 23, 12384 (2022).","DOI":"10.3390\/ijms232012384"},{"key":"2326_CR118","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2020.00195","volume":"11","author":"YJ Park","year":"2020","unstructured":"Park, Y. J., Yoo, S. A., Kim, M. & Kim, W. U. The role of calcium-calcineurin-NFAT signaling pathway in health and autoimmune diseases. Front. Immunol. 11, 195 (2020).","journal-title":"Front. Immunol."},{"key":"2326_CR119","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jir.2015.0054","volume":"36","author":"A Rani","year":"2016","unstructured":"Rani, A. & Murphy, J. J. STAT5 in cancer and immunity. J. Interferon Cytokine Res. 36, 226\u2013237 (2016).","journal-title":"J. Interferon Cytokine Res."},{"key":"2326_CR120","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/eji.202048794","volume":"51","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Transcriptional and posttranslational regulation of Th17\/Treg balance in health and disease. Eur. J. Immunol. 51, 2137\u20132150 (2021).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR121","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1084\/jem.20070109","volume":"204","author":"HP Kim","year":"2007","unstructured":"Kim, H. P. & Leonard, W. J. CREB\/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J. Exp. Med. 204, 1543\u20131551 (2007).","journal-title":"J. Exp. Med."},{"key":"2326_CR122","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ni1549","volume":"9","author":"Y Tone","year":"2008","unstructured":"Tone, Y. et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9, 194\u2013202 (2008).","journal-title":"Nat. Immunol."},{"key":"2326_CR123","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2021.03.020","volume":"54","author":"S Dikiy","year":"2021","unstructured":"Dikiy, S. et al. A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity 54, 931\u2013946.e911 (2021).","journal-title":"Immunity"},{"key":"2326_CR124","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2021.04.005","volume":"54","author":"R Kawakami","year":"2021","unstructured":"Kawakami, R. et al. Distinct Foxp3 enhancer elements coordinate development, maintenance, and function of regulatory T cells. Immunity 54, 947\u2013961.e948 (2021).","journal-title":"Immunity"},{"key":"2326_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110124","volume":"37","author":"J Li","year":"2021","unstructured":"Li, J. et al. Control of Foxp3 induction and maintenance by sequential histone acetylation and DNA demethylation. Cell Rep. 37, 110124 (2021).","journal-title":"Cell Rep."},{"key":"2326_CR126","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.0050038","volume":"5","author":"S Floess","year":"2007","unstructured":"Floess, S. et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5, e38 (2007).","journal-title":"PLoS Biol."},{"key":"2326_CR127","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1126\/science.1191996","volume":"329","author":"YP Rubtsov","year":"2010","unstructured":"Rubtsov, Y. P. et al. Stability of the regulatory T cell lineage in vivo. Science 329, 1667\u20131671 (2010).","journal-title":"Science"},{"key":"2326_CR128","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ni.1795","volume":"10","author":"D Rudra","year":"2009","unstructured":"Rudra, D. et al. Runx-CBFbeta complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 10, 1170\u20131177 (2009).","journal-title":"Nat. Immunol."},{"key":"2326_CR129","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2009.09.003","volume":"31","author":"A Kitoh","year":"2009","unstructured":"Kitoh, A. et al. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity 31, 609\u2013620 (2009).","journal-title":"Immunity"},{"key":"2326_CR130","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-018-1521-3","volume":"20","author":"R Saigusa","year":"2018","unstructured":"Saigusa, R. et al. Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells. Arthritis Res. Ther. 20, 23 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"2326_CR131","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1073\/pnas.0900621106","volume":"106","author":"M Ayyoub","year":"2009","unstructured":"Ayyoub, M. et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc. Natl. Acad. Sci. USA 106, 8635\u20138640 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR132","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000\u20131007 (2009).","journal-title":"Nat. Immunol."},{"key":"2326_CR133","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nm.2389","volume":"17","author":"M Dominguez-Villar","year":"2011","unstructured":"Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17, 673\u2013675 (2011).","journal-title":"Nat. Med."},{"key":"2326_CR134","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/CIRCRESAHA.116.309764","volume":"119","author":"MJ Butcher","year":"2016","unstructured":"Butcher, M. J. et al. Atherosclerosis-driven Treg plasticity results in formation of a dysfunctional subset of plastic IFNgamma+ Th1\/Tregs. Circ. Res. 119, 1190\u20131203 (2016).","journal-title":"Circ. Res."},{"issue":"Suppl 124","key":"2326_CR135","first-page":"48","volume":"38","author":"N Gao","year":"2020","unstructured":"Gao, N., et al. Contribution of Th2-like Treg cells to the pathogenesis of Takayasu\u2019s arteritis. Clin. Exp. Rheumatol. 38(Suppl 124), 48\u201354 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2326_CR136","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.celrep.2017.06.079","volume":"20","author":"L Halim","year":"2017","unstructured":"Halim, L. et al. An atlas of human regulatory T helper-like cells reveals features of Th2-like Tregs that support a tumorigenic environment. Cell Rep. 20, 757\u2013770 (2017).","journal-title":"Cell Rep."},{"key":"2326_CR137","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.4049\/jimmunol.1201794","volume":"189","author":"DV Sawant","year":"2012","unstructured":"Sawant, D. V. et al. Bcl6 controls the Th2 inflammatory activity of regulatory T cells by repressing Gata3 function. J. Immunol. 189, 4759\u20134769 (2012).","journal-title":"J. Immunol."},{"key":"2326_CR138","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","volume":"112","author":"HJ Koenen","year":"2008","unstructured":"Koenen, H. J. et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340\u20132352 (2008).","journal-title":"Blood"},{"key":"2326_CR139","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121\u20131133 (2006).","journal-title":"Cell"},{"key":"2326_CR140","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1182\/blood-2008-10-183251","volume":"113","author":"G Beriou","year":"2009","unstructured":"Beriou, G. et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113, 4240\u20134249 (2009).","journal-title":"Blood"},{"key":"2326_CR141","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1073\/pnas.0900408106","volume":"106","author":"KS Voo","year":"2009","unstructured":"Voo, K. S. et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc. Natl. Acad. Sci. USA 106, 4793\u20134798 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR142","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature06878","volume":"453","author":"L Zhou","year":"2008","unstructured":"Zhou, L. et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453, 236\u2013240 (2008).","journal-title":"Nature"},{"key":"2326_CR143","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nm.2425","volume":"17","author":"MA Linterman","year":"2011","unstructured":"Linterman, M. A. et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat. Med. 17, 975\u2013982 (2011).","journal-title":"Nat. Med."},{"key":"2326_CR144","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nm.2426","volume":"17","author":"Y Chung","year":"2011","unstructured":"Chung, Y. et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat. Med. 17, 983\u2013988 (2011).","journal-title":"Nat. Med."},{"key":"2326_CR145","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41423-022-00840-x","volume":"19","author":"H Chi","year":"2022","unstructured":"Chi, H. Immunometabolism at the intersection of metabolic signaling, cell fate, and systems immunology. Cell. Mol. Immunol. 19, 299\u2013302 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"2326_CR146","doi-asserted-by":"publisher","first-page":"eaar3932","DOI":"10.1126\/science.aar3932","volume":"363","author":"A Wang","year":"2019","unstructured":"Wang, A., Luan, H. H. & Medzhitov, R. An evolutionary perspective on immunometabolism. Science 363, eaar3932 (2019).","journal-title":"Science"},{"key":"2326_CR147","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.4049\/jimmunol.181.4.2277","volume":"181","author":"S Xiao","year":"2008","unstructured":"Xiao, S. et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 181, 2277\u20132284 (2008).","journal-title":"J. Immunol."},{"key":"2326_CR148","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1084\/jem.20151438","volume":"213","author":"X Yue","year":"2016","unstructured":"Yue, X. et al. Control of Foxp3 stability through modulation of TET activity. J. Exp. Med. 213, 377\u2013397 (2016).","journal-title":"J. Exp. Med."},{"key":"2326_CR149","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.4049\/jimmunol.1502352","volume":"196","author":"V Sasidharan Nair","year":"2016","unstructured":"Sasidharan Nair, V., Song, M. H. & Oh, K. I. Vitamin C facilitates demethylation of the Foxp3 enhancer in a tet-dependent manner. J. Immunol. 196, 2119\u20132131 (2016).","journal-title":"J. Immunol."},{"key":"2326_CR150","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1128\/MCB.05020-11","volume":"31","author":"S Joshi","year":"2011","unstructured":"Joshi, S. et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell Biol. 31, 3653\u20133669 (2011).","journal-title":"Mol. Cell Biol."},{"key":"2326_CR151","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.4049\/jimmunol.0803217","volume":"183","author":"LE Jeffery","year":"2009","unstructured":"Jeffery, L. E. et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183, 5458\u20135467 (2009).","journal-title":"J. Immunol."},{"key":"2326_CR152","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.4049\/jimmunol.1101211","volume":"188","author":"SW Kang","year":"2012","unstructured":"Kang, S. W. et al. 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J. Immunol. 188, 5276\u20135282 (2012).","journal-title":"J. Immunol."},{"key":"2326_CR153","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"RD Michalek","year":"2011","unstructured":"Michalek, R. D. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186, 3299\u20133303 (2011).","journal-title":"J. Immunol."},{"key":"2326_CR154","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","volume":"153","author":"CH Chang","year":"2013","unstructured":"Chang, C. H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239\u20131251 (2013).","journal-title":"Cell"},{"key":"2326_CR155","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","volume":"25","author":"A Angelin","year":"2017","unstructured":"Angelin, A. et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 25, 1282\u20131293.e1287 (2017).","journal-title":"Cell Metab."},{"key":"2326_CR156","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221352120","volume":"120","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. SRC2 controls CD4(+) T cell activation via stimulating c-Myc-mediated upregulation of amino acid transporter Slc7a5. Proc. Natl. Acad. Sci. USA 120, e2221352120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR157","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cmet.2019.11.021","volume":"31","author":"CS Field","year":"2020","unstructured":"Field, C. S. et al. Mitochondrial integrity regulated by lipid metabolism is a cell-intrinsic checkpoint for Treg suppressive function. Cell Metab. 31, 422\u2013437.e425 (2020).","journal-title":"Cell Metab."},{"key":"2326_CR158","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41590-023-01672-1","volume":"25","author":"L Lin","year":"2024","unstructured":"Lin, L. et al. Oleic acid availability impacts thymocyte preprogramming and subsequent peripheral T(reg) cell differentiation. Nat. Immunol. 25, 54\u201365 (2024).","journal-title":"Nat. Immunol."},{"key":"2326_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00849-9","volume":"20","author":"Y Miao","year":"2022","unstructured":"Miao, Y. et al. The activation of PPARgamma enhances Treg responses through up-regulating CD36\/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TbetaRII\/IL-2Ralpha. Cell Commun. Signal 20, 48 (2022).","journal-title":"Cell Commun. Signal"},{"key":"2326_CR160","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan, Y. et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J. Hematol. Oncol. 15, 104 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2326_CR161","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 21, 298\u2013308 (2020).","journal-title":"Nat. Immunol."},{"key":"2326_CR162","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6443","volume":"6","author":"J Saravia","year":"2020","unstructured":"Saravia, J. et al. Homeostasis and transitional activation of regulatory T cells require c-Myc. Sci. Adv. 6, eaaw6443 (2020).","journal-title":"Sci. Adv."},{"key":"2326_CR163","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s42255-022-00576-y","volume":"4","author":"E Danileviciute","year":"2022","unstructured":"Danileviciute, E. et al. PARK7\/DJ-1 promotes pyruvate dehydrogenase activity and maintains T(reg) homeostasis during ageing. Nat. Metab. 4, 589\u2013607 (2022).","journal-title":"Nat. Metab."},{"key":"2326_CR164","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.immuni.2021.10.011","volume":"55","author":"A Sugiura","year":"2022","unstructured":"Sugiura, A. et al. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity 55, 65\u201381.e69 (2022).","journal-title":"Immunity"},{"key":"2326_CR165","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41580-020-00313-x","volume":"22","author":"AJ Covarrubias","year":"2021","unstructured":"Covarrubias, A. J., Perrone, R., Grozio, A. & Verdin, E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 22, 119\u2013141 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2326_CR166","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41590-022-01373-1","volume":"24","author":"MJ Kim","year":"2023","unstructured":"Kim, M. J. et al. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nat. Immunol. 24, 148\u2013161 (2023).","journal-title":"Nat. Immunol."},{"key":"2326_CR167","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada, T. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl. Acad. Sci. USA 116, 9999\u201310008 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR168","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s42255-022-00575-z","volume":"4","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. Non-oxidative pentose phosphate pathway controls regulatory T cell function by integrating metabolism and epigenetics. Nat. Metab. 4, 559\u2013574 (2022).","journal-title":"Nat. Metab."},{"key":"2326_CR169","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41586-018-0846-z","volume":"565","author":"SE Weinberg","year":"2019","unstructured":"Weinberg, S. E. et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature 565, 495\u2013499 (2019).","journal-title":"Nature"},{"key":"2326_CR170","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/emboj.2009.210","volume":"28","author":"C Huang","year":"2009","unstructured":"Huang, C. et al. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO j. 28, 2748\u20132762 (2009).","journal-title":"EMBO j."},{"key":"2326_CR171","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/emboj.2010.245","volume":"29","author":"S Yan","year":"2010","unstructured":"Yan, S. et al. Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J. 29, 3773\u20133786 (2010).","journal-title":"EMBO J."},{"key":"2326_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05676-6","volume":"9","author":"X Yu","year":"2018","unstructured":"Yu, X. et al. SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation. Nat. Commun. 9, 3157 (2018).","journal-title":"Nat. Commun."},{"key":"2326_CR173","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2017.10.017","volume":"47","author":"M Kishore","year":"2017","unstructured":"Kishore, M. et al. Regulatory T cell migration is dependent on glucokinase-mediated glycolysis. Immunity 47, 875\u2013889.e810 (2017).","journal-title":"Immunity"},{"key":"2326_CR174","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4049\/jimmunol.1901480","volume":"205","author":"R Vallion","year":"2020","unstructured":"Vallion, R. et al. Regulatory T cell stability and migration are dependent on mTOR. J. Immunol. 205, 1799\u20131809 (2020).","journal-title":"J. Immunol."},{"key":"2326_CR175","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/eji.200838318","volume":"38","author":"J Ben-Shoshan","year":"2008","unstructured":"Ben-Shoshan, J. et al. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur. J. Immunol. 38, 2412\u20132418 (2008).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR176","doi-asserted-by":"publisher","first-page":"E2784","DOI":"10.1073\/pnas.1202366109","volume":"109","author":"ET Clambey","year":"2012","unstructured":"Clambey, E. T. et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. USA 109, E2784\u2013E2793 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR177","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","volume":"27","author":"J Miska","year":"2019","unstructured":"Miska, J. et al. HIF-1\u03b1 is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. Cell Rep. 27, 226\u2013237.e224 (2019).","journal-title":"Cell Rep."},{"key":"2326_CR178","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.immuni.2015.05.016","volume":"42","author":"JH Lee","year":"2015","unstructured":"Lee, J. H., Elly, C., Park, Y. & Liu, Y. C. E3 Ubiquitin ligase VHL regulates hypoxia-inducible factor-1\u03b1 to Maintain Regulatory T cell stability and suppressive capacity. Immunity 42, 1062\u20131074 (2015).","journal-title":"Immunity"},{"key":"2326_CR179","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cmet.2018.09.020","volume":"29","author":"L Li","year":"2019","unstructured":"Li, L. et al. TLR8-mediated metabolic control of human Treg function: a mechanistic target for cancer immunotherapy. Cell Metab. 29, 103\u2013123.e105 (2019).","journal-title":"Cell Metab."},{"key":"2326_CR180","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","volume":"249","author":"GJ van der Windt","year":"2012","unstructured":"van der Windt, G. J. & Pearce, E. L. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol. Rev. 249, 27\u201342 (2012).","journal-title":"Immunol. Rev."},{"key":"2326_CR181","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1073\/pnas.0308061100","volume":"101","author":"RJ Shaw","year":"2004","unstructured":"Shaw, R. J. et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 101, 3329\u20133335 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR182","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.cub.2003.10.031","volume":"13","author":"A Woods","year":"2003","unstructured":"Woods, A. et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004\u20132008 (2003).","journal-title":"Curr. Biol."},{"key":"2326_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15876","volume":"8","author":"D Wu","year":"2017","unstructured":"Wu, D. et al. Lkb1 maintains T(reg) cell lineage identity. Nat. Commun. 8, 15876 (2017).","journal-title":"Nat. Commun."},{"key":"2326_CR184","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1016\/j.celrep.2019.05.020","volume":"27","author":"M Timilshina","year":"2019","unstructured":"Timilshina, M. et al. Activation of mevalonate pathway via LKB1 is essential for stability of T(reg) cells. Cell Rep. 27, 2948\u20132961.e2947 (2019).","journal-title":"Cell Rep."},{"key":"2326_CR185","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature23665","volume":"548","author":"K Yang","year":"2017","unstructured":"Yang, K. et al. Homeostatic control of metabolic and functional fitness of T(reg) cells by LKB1 signalling. Nature 548, 602\u2013606 (2017).","journal-title":"Nature"},{"key":"2326_CR186","doi-asserted-by":"publisher","first-page":"12542","DOI":"10.1073\/pnas.1715363114","volume":"114","author":"N He","year":"2017","unstructured":"He, N. et al. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. Proc. Natl. Acad. Sci. USA 114, 12542\u201312547 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR187","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.immuni.2019.10.001","volume":"51","author":"H Shi","year":"2019","unstructured":"Shi, H. et al. Amino acids license kinase mTORC1 activity and Treg cell function via small G proteins Rag and Rheb. Immunity 51, 1012\u20131027.e1017 (2019).","journal-title":"Immunity"},{"key":"2326_CR188","doi-asserted-by":"publisher","first-page":"e20190848","DOI":"10.1084\/jem.20190848","volume":"217","author":"MH Do","year":"2020","unstructured":"Do, M. H. et al. Nutrient mTORC1 signaling underpins regulatory T cell control of immune tolerance. J. Exp. Med. 217, e20190848 (2020).","journal-title":"J. Exp. Med."},{"key":"2326_CR189","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature13577","volume":"513","author":"C Schiering","year":"2014","unstructured":"Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564\u2013568 (2014).","journal-title":"Nature"},{"key":"2326_CR190","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cmet.2015.03.005","volume":"21","author":"D Kolodin","year":"2015","unstructured":"Kolodin, D. et al. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab. 21, 543\u2013557 (2015).","journal-title":"Cell Metab."},{"key":"2326_CR191","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2018.05.004","volume":"174","author":"C Li","year":"2018","unstructured":"Li, C. et al. TCR transgenic mice reveal stepwise, multi-site acquisition of the distinctive fat-Treg phenotype. Cell 174, 285\u2013299.e212 (2018).","journal-title":"Cell"},{"key":"2326_CR192","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.immuni.2019.12.002","volume":"52","author":"M Delacher","year":"2020","unstructured":"Delacher, M. et al. Precursors for nonlymphoid-tissue Treg cells reside in secondary lymphoid organs and are programmed by the transcription factor BATF. Immunity 52, 295\u2013312.e211 (2020).","journal-title":"Immunity"},{"key":"2326_CR193","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.it.2015.10.002","volume":"36","author":"A Vasanthakumar","year":"2015","unstructured":"Vasanthakumar, A. & Kallies, A. The regulatory T cell: jack-of-all-trades. Trends Immunol. 36, 756\u2013758 (2015).","journal-title":"Trends Immunol."},{"key":"2326_CR194","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41590-021-00889-2","volume":"22","author":"J Quandt","year":"2021","unstructured":"Quandt, J. et al. Wnt-beta-catenin activation epigenetically reprograms T(reg) cells in inflammatory bowel disease and dysplastic progression. Nat. Immunol. 22, 471\u2013484 (2021).","journal-title":"Nat. Immunol."},{"key":"2326_CR195","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1016\/j.ajpath.2015.08.010","volume":"185","author":"E Gazzerro","year":"2015","unstructured":"Gazzerro, E. et al. Enhancement of muscle T regulatory cells and improvement of muscular dystrophic process in MDX mice by blockade of extracellular ATP\/P2X axis. Am. J. Pathol. 185, 3349\u20133360 (2015).","journal-title":"Am. J. Pathol."},{"key":"2326_CR196","doi-asserted-by":"publisher","first-page":"ra12","DOI":"10.1126\/scisignal.2001270","volume":"4","author":"U Schenk","year":"2011","unstructured":"Schenk, U. et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci. Signal. 4, ra12 (2011).","journal-title":"Sci. Signal."},{"key":"2326_CR197","doi-asserted-by":"publisher","first-page":"258ra142","DOI":"10.1126\/scitranslmed.3009925","volume":"6","author":"SA Villalta","year":"2014","unstructured":"Villalta, S. A. et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 6, 258ra142 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2326_CR198","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.celrep.2019.01.070","volume":"26","author":"G Garg","year":"2019","unstructured":"Garg, G. et al. Blimp1 prevents methylation of Foxp3 and loss of regulatory T cell identity at sites of inflammation. Cell Rep. 26, 1854\u20131868.e1855 (2019).","journal-title":"Cell Rep."},{"key":"2326_CR199","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrm3274","volume":"13","author":"EJ Wagner","year":"2012","unstructured":"Wagner, E. J. & Carpenter, P. B. Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 13, 115\u2013126 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2326_CR200","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11282-x","volume":"10","author":"Z Ji","year":"2019","unstructured":"Ji, Z. et al. The histone methyltransferase Setd2 is indispensable for V(D)J recombination. Nat. Commun. 10, 3353 (2019).","journal-title":"Nat. Commun."},{"key":"2326_CR201","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41588-019-0398-7","volume":"51","author":"Q Xu","year":"2019","unstructured":"Xu, Q. et al. SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development. Nat. Genet 51, 844\u2013856 (2019).","journal-title":"Nat. Genet"},{"key":"2326_CR202","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1073\/pnas.0915033107","volume":"107","author":"M Hu","year":"2010","unstructured":"Hu, M. et al. Histone H3 lysine 36 methyltransferase Hypb\/Setd2 is required for embryonic vascular remodeling. Proc. Natl. Acad. Sci. USA 107, 2956\u20132961 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR203","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.cell.2017.06.042","volume":"170","author":"K Chen","year":"2017","unstructured":"Chen, K. et al. Methyltransferase SETD2-Mediated Methylation of STAT1 is critical for interferon antiviral activity. Cell 170, 492\u2013506.e414 (2017).","journal-title":"Cell"},{"key":"2326_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35250-0","volume":"13","author":"Z Ding","year":"2022","unstructured":"Ding, Z. et al. Setd2 supports GATA3+ST2+ thymic-derived Treg cells and suppresses intestinal inflammation. Nat. Commun. 13, 7468 (2022).","journal-title":"Nat. Commun."},{"key":"2326_CR205","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7662","volume":"8","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Steroid nuclear receptor coactivator 2 controls immune tolerance by promoting induced T(reg) differentiation via up-regulating Nr4a2. Sci. Adv. 8, eabn7662 (2022).","journal-title":"Sci. Adv."},{"key":"2326_CR206","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4274","volume":"10","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Cancer-associated SF3B1-K700E mutation controls immune responses by regulating T(reg) function via aberrant Anapc13 splicing. Sci. Adv. 10, eado4274 (2024).","journal-title":"Sci. Adv."},{"key":"2326_CR207","doi-asserted-by":"crossref","unstructured":"Wang, A. et al. ZFP91 is required for the maintenance of regulatory T cell homeostasis and function. J Exp. Med. 218, e20201217 (2021).","DOI":"10.1084\/jem.20201217"},{"key":"2326_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30707-8","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. The Ube2m-Rbx1 neddylation-Cullin-RING-Ligase proteins are essential for the maintenance of Regulatory T cell fitness. Nat. Commun. 13, 3021 (2022).","journal-title":"Nat. Commun."},{"key":"2326_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50392-z","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. RNF213 promotes Treg cell differentiation by facilitating K63-linked ubiquitination and nuclear translocation of FOXO1. Nat. Commun. 15, 5961 (2024).","journal-title":"Nat. Commun."},{"key":"2326_CR210","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4116","volume":"8","author":"E Montauti","year":"2022","unstructured":"Montauti, E. et al. A deubiquitination module essential for T(reg) fitness in the tumor microenvironment. Sci. Adv. 8, eabo4116 (2022).","journal-title":"Sci. Adv."},{"key":"2326_CR211","doi-asserted-by":"publisher","first-page":"e20190711","DOI":"10.1084\/jem.20190711","volume":"217","author":"FM Grant","year":"2020","unstructured":"Grant, F. M. et al. BACH2 drives quiescence and maintenance of resting Treg cells to promote homeostasis and cancer immunosuppression. J. Exp. Med. 217, e20190711 (2020).","journal-title":"J. Exp. Med."},{"key":"2326_CR212","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-021-00741-9","volume":"18","author":"F Rosetti","year":"2022","unstructured":"Rosetti, F., Madera-Salcedo, I. K., Rodriguez-Rodriguez, N. & Crispin, J. C. Regulation of activated T cell survival in rheumatic autoimmune diseases. Nat. Rev. Rheumatol. 18, 232\u2013244 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2326_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.716081","volume":"12","author":"X Li","year":"2021","unstructured":"Li, X. et al. Dysfunctions, molecular mechanisms, and therapeutic strategies of regulatory T cells in rheumatoid arthritis. Front. Pharm. 12, 716081 (2021).","journal-title":"Front. Pharm."},{"key":"2326_CR214","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1073\/pnas.1112722108","volume":"108","author":"PA Beavis","year":"2011","unstructured":"Beavis, P. A. et al. Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc. Natl. Acad. Sci. USA 108, 16717\u201316722 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR215","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00018-022-04563-0","volume":"79","author":"S Yan","year":"2022","unstructured":"Yan, S., Kotschenreuther, K., Deng, S. & Kofler, D. M. Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential. Cell Mol. Life Sci. 79, 533 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"2326_CR216","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8575407","volume":"2019","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. Efficient therapeutic function and mechanisms of human polyclonal CD8(+)CD103(+)Foxp3(+) regulatory T cells on collagen-induced arthritis in mice. J. Immunol. Res. 2019, 8575407 (2019).","journal-title":"J. Immunol. Res."},{"key":"2326_CR217","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi9591","volume":"376","author":"J Li","year":"2022","unstructured":"Li, J. et al. KIR(+)CD8(+) T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science 376, eabi9591 (2022).","journal-title":"Science"},{"key":"2326_CR218","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh, C. H. et al. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp. Mol. Med. 55, 2287\u20132299 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2326_CR219","doi-asserted-by":"publisher","first-page":"108858","DOI":"10.1016\/j.intimp.2022.108858","volume":"108","author":"F Rezaei Kahmini","year":"2022","unstructured":"Rezaei Kahmini, F., Shahgaldi, S., Azimi, M. & Mansourabadi, A. H. Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: new insights and challenges. Int. Immunopharmacol. 108, 108858 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"2326_CR220","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1016\/j.cell.2021.05.028","volume":"184","author":"HS Wong","year":"2021","unstructured":"Wong, H. S. et al. A local regulatory T cell feedback circuit maintains immune homeostasis by pruning self-activated T cells. Cell 184, 3981\u20133997 e3922 (2021).","journal-title":"Cell"},{"key":"2326_CR221","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"A Hosseini","year":"2020","unstructured":"Hosseini, A. et al. CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol. 80, 106221 (2020).","journal-title":"Int Immunopharmacol."},{"key":"2326_CR222","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/art.42795","volume":"76","author":"Y Fang","year":"2024","unstructured":"Fang, Y. et al. Epigenetic regulatory axis MIR22-TET3-MTRNR2L2 represses fibroblast-like synoviocyte-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 76, 845\u2013856 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"2326_CR223","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4049\/jimmunol.1401145","volume":"194","author":"M Rossetti","year":"2015","unstructured":"Rossetti, M. et al. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J. Immunol. 194, 113\u2013124 (2015).","journal-title":"J. Immunol."},{"key":"2326_CR224","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1093\/rheumatology\/keae196","volume":"63","author":"H Yoshida","year":"2024","unstructured":"Yoshida, H. et al. Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis. Rheumatology 63, 2515\u20132524 (2024).","journal-title":"Rheumatology"},{"key":"2326_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53255-9","volume":"15","author":"A Eugster","year":"2024","unstructured":"Eugster, A. et al. Physiological and pathogenic T cell autoreactivity converge in type 1 diabetes. Nat. Commun. 15, 9204 (2024).","journal-title":"Nat. Commun."},{"key":"2326_CR226","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dbi18-0058","volume":"70","author":"M Bettini","year":"2021","unstructured":"Bettini, M. & Bettini, M. L. Function, failure, and the future potential of Tregs in type 1 diabetes. Diabetes 70, 1211\u20131219 (2021).","journal-title":"Diabetes"},{"key":"2326_CR227","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ng2068","volume":"39","author":"JA Todd","year":"2007","unstructured":"Todd, J. A. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet 39, 857\u2013864 (2007).","journal-title":"Nat. Genet"},{"key":"2326_CR228","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1172\/JCI0213605","volume":"109","author":"A Kukreja","year":"2002","unstructured":"Kukreja, A. et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest 109, 131\u2013140 (2002).","journal-title":"J. Clin. Invest"},{"key":"2326_CR229","doi-asserted-by":"crossref","unstructured":"Santoso, C. et al. Autoimmune diseases and the risk and prognosis of latent autoimmune diabetes in adults. Diabetologia 68, 331\u2013341 (2024).","DOI":"10.1007\/s00125-024-06303-4"},{"key":"2326_CR230","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","volume":"31","author":"CE Sutton","year":"2009","unstructured":"Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331\u2013341 (2009).","journal-title":"Immunity"},{"key":"2326_CR231","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","volume":"22","author":"KE Attfield","year":"2022","unstructured":"Attfield, K. E. et al. The immunology of multiple sclerosis. Nat. Rev. Immunol. 22, 734\u2013750 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2326_CR232","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/13696998.2017.1355310","volume":"20","author":"H Yang","year":"2017","unstructured":"Yang, H. et al. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J. Med. Econ. 20, 1056\u20131065 (2017).","journal-title":"J. Med. Econ."},{"key":"2326_CR233","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2326_CR234","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med.367, 1087\u20131097 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2326_CR235","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fimmu.2019.00159","volume":"10","author":"W Li","year":"2019","unstructured":"Li, W., Deng, C., Yang, H. & Wang, G. The regulatory T cell in active systemic lupus erythematosus patients: a systemic review and meta-analysis. Front. Immunol. 10, 159 (2019).","journal-title":"Front. Immunol."},{"key":"2326_CR236","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2326_CR237","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2326_CR238","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","volume":"57","author":"ME Raeber","year":"2024","unstructured":"Raeber, M. E. et al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity 57, 2232\u20132250 e2210 (2024).","journal-title":"Immunity"},{"key":"2326_CR239","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1325946","volume":"15","author":"D Qin","year":"2024","unstructured":"Qin, D. et al. Targeting tumor-infiltrating tregs for improved antitumor responses. Front. Immunol. 15, 1325946 (2024).","journal-title":"Front. Immunol."},{"key":"2326_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li, C. et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer 19, 116 (2020).","journal-title":"Mol. Cancer"},{"key":"2326_CR241","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1002\/ijc.24989","volume":"126","author":"DM Frey","year":"2010","unstructured":"Frey, D. M. et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 126, 2635\u20132643 (2010).","journal-title":"Int. J. Cancer"},{"key":"2326_CR242","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-11-3216","volume":"18","author":"RJ deLeeuw","year":"2012","unstructured":"deLeeuw, R. J., Kost, S. E., Kakal, J. A. & Nelson, B. H. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin. Cancer Res. 18, 3022\u20133029 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2326_CR243","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s41379-022-01086-8","volume":"35","author":"CH Bergsland","year":"2022","unstructured":"Bergsland, C. H. et al. Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Mod. Pathol. 35, 1236\u20131246 (2022).","journal-title":"Mod. Pathol."},{"key":"2326_CR244","doi-asserted-by":"publisher","first-page":"e2114282119","DOI":"10.1073\/pnas.2114282119","volume":"119","author":"Y Kidani","year":"2022","unstructured":"Kidani, Y. et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proc. Natl. Acad. Sci. USA 119, e2114282119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR245","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay, C., Tanaka, A. & Sakaguchi, S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41, 450\u2013465 (2023).","journal-title":"Cancer Cell"},{"key":"2326_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37614-6","volume":"14","author":"L Gong","year":"2023","unstructured":"Gong, L. et al. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. Nat. Commun. 14, 1912 (2023).","journal-title":"Nat. Commun."},{"key":"2326_CR247","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, J., Nakahata, S. & Iha, H. Complex role of regulatory T cells (Tregs) in the Tumor microenvironment: their molecular mechanisms and bidirectional effects on cancer progression. Int. J. Mol. Sci. 25, 7346 (2024).","DOI":"10.3390\/ijms25137346"},{"key":"2326_CR248","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01714-0","volume":"22","author":"M Iglesias-Escudero","year":"2023","unstructured":"Iglesias-Escudero, M., Arias-Gonzalez, N. & Martinez-Caceres, E. Regulatory cells and the effect of cancer immunotherapy. Mol. Cancer 22, 26 (2023).","journal-title":"Mol. Cancer"},{"key":"2326_CR249","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s40425-019-0785-8","volume":"7","author":"HR Kim","year":"2019","unstructured":"Kim, H. R. et al. Tumor microenvironment dictates regulatory T cell phenotype: upregulated immune checkpoints reinforce suppressive function. J. Immunother. Cancer 7, 339 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2326_CR250","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00630-9","volume":"12","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy. Biomark. Res. 12, 97 (2024).","journal-title":"Biomark. Res."},{"key":"2326_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107126","volume":"202","author":"Q Lv","year":"2024","unstructured":"Lv, Q. et al. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharm. Res. 202, 107126 (2024).","journal-title":"Pharm. Res."},{"key":"2326_CR252","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403 (2023).","journal-title":"Cancer Cell"},{"key":"2326_CR253","doi-asserted-by":"publisher","first-page":"943354","DOI":"10.3389\/fimmu.2022.943354","volume":"13","author":"K Maharaj","year":"2022","unstructured":"Maharaj, K., Uriepero, A., Sahakian, E. & Pinilla-Ibarz, J. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Front. Immunol. 13, 943354 (2022).","journal-title":"Front. Immunol."},{"key":"2326_CR254","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.25752","volume":"117","author":"L Weiss","year":"2011","unstructured":"Weiss, L. et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 117, 2163\u20132169 (2011).","journal-title":"Cancer"},{"key":"2326_CR255","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.1182\/bloodadvances.2023010158","volume":"7","author":"I Spasevska","year":"2023","unstructured":"Spasevska, I. et al. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Adv. 7, 7216\u20137230 (2023).","journal-title":"Blood Adv."},{"key":"2326_CR256","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1158\/2326-6066.CIR-15-0168","volume":"4","author":"AC Jaime-Ramirez","year":"2016","unstructured":"Jaime-Ramirez, A. C. et al. NK cell-mediated antitumor effects of a folate-conjugated immunoglobulin are enhanced by cytokines. Cancer Immunol. Res. 4, 323\u2013336 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR257","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.21873\/anticanres.16588","volume":"43","author":"SY Sur","year":"2023","unstructured":"Sur, S. Y. et al. Anti-tumor effect of activated canine B cells with interleukin-21 and anti-B cell receptor. Anticancer Res. 43, 4007\u20134014 (2023).","journal-title":"Anticancer Res."},{"key":"2326_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101826","volume":"5","author":"V Rubino","year":"2024","unstructured":"Rubino, V. et al. IL-21\/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. Cell Rep. Med. 5, 101826 (2024).","journal-title":"Cell Rep. Med."},{"key":"2326_CR259","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1182\/blood.2020010527","volume":"138","author":"P Balsas","year":"2021","unstructured":"Balsas, P. et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood 138, 2202\u20132215 (2021).","journal-title":"Blood"},{"key":"2326_CR260","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332\u20131341 (2017).","journal-title":"Nat. Immunol."},{"key":"2326_CR261","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/2326-6066.CIR-15-0050","volume":"4","author":"P Sundstrom","year":"2016","unstructured":"Sundstrom, P. et al. Regulatory T cells from colon cancer patients inhibit effector T-cell migration through an adenosine-dependent mechanism. Cancer Immunol. Res. 4, 183\u2013193 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR262","doi-asserted-by":"crossref","unstructured":"Elias, S. et al. CXCR4+ Treg cells control serum IgM levels and natural IgM autoantibody production by B-1 cells in the bone marrow. J. Exp. Med. 219, e20220047 (2022).","DOI":"10.1084\/jem.20220047"},{"key":"2326_CR263","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678355","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. The alterations in and the role of the Th17\/Treg balance in metabolic diseases. Front Immunol. 12, 678355 (2021).","journal-title":"Front Immunol."},{"key":"2326_CR264","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1055\/s-0043-113454","volume":"126","author":"N Yuan","year":"2018","unstructured":"Yuan, N. et al. Expression of CD4+CD25+Foxp3+ regulatory T cells, interleukin 10 and transforming growth factor beta in newly diagnosed type 2 diabetic patients. Exp. Clin. Endocrinol. Diab 126, 96\u2013101 (2018).","journal-title":"Exp. Clin. Endocrinol. Diab"},{"key":"2326_CR265","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41423-018-0004-4","volume":"15","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann, H. M. et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol. Immunol. 15, 458\u2013469 (2018).","journal-title":"Cell Mol. Immunol."},{"key":"2326_CR266","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41574-023-00932-2","volume":"20","author":"SR Shaikh","year":"2024","unstructured":"Shaikh, S. R., Beck, M. A., Alwarawrah, Y. & MacIver, N. J. Emerging mechanisms of obesity-associated immune dysfunction. Nat. Rev. Endocrinol. 20, 136\u2013148 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2326_CR267","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s43587-023-00439-5","volume":"3","author":"Y Ma","year":"2023","unstructured":"Ma, Y. & Cao, H. Lnc-ing\u2019 T(reg) cells to the aging liver. Nat. Aging 3, 760\u2013761 (2023).","journal-title":"Nat. Aging"},{"key":"2326_CR268","doi-asserted-by":"publisher","first-page":"652","DOI":"10.7150\/ijms.83317","volume":"20","author":"L Tang","year":"2023","unstructured":"Tang, L. et al. Dysfunction of circulating CD3(+)CD56(+) NKT-like cells in type 2 diabetes mellitus. Int. J. Med. Sci. 20, 652\u2013662 (2023).","journal-title":"Int. J. Med. Sci."},{"key":"2326_CR269","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fimmu.2018.00883","volume":"9","author":"A Sharma","year":"2018","unstructured":"Sharma, A. & Rudra, D. Emerging functions of regulatory T cells in tissue homeostasis. Front. Immunol. 9, 883 (2018).","journal-title":"Front. Immunol."},{"key":"2326_CR270","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-065X.2009.00775.x","volume":"229","author":"H Bour-Jordan","year":"2009","unstructured":"Bour-Jordan, H. & Bluestone, J. A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41\u201366 (2009).","journal-title":"Immunol. Rev."},{"key":"2326_CR271","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S2213-8587(15)00254-5","volume":"3","author":"P Berman","year":"2015","unstructured":"Berman, P., Davies, J. & Horton, R. Diabetes, obesity, and the metabolic syndrome: a call for papers for EASD and the World Diabetes Congress. Lancet Diab Endocrinol. 3, 591 (2015).","journal-title":"Lancet Diab Endocrinol."},{"key":"2326_CR272","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature11132","volume":"486","author":"D Cipolletta","year":"2012","unstructured":"Cipolletta, D. et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549\u2013553 (2012).","journal-title":"Nature"},{"key":"2326_CR273","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cmet.2021.06.007","volume":"33","author":"C Li","year":"2021","unstructured":"Li, C. et al. Interferon-alpha-producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory T cells during obesity. Cell Metab. 33, 1610\u20131623 e1615 (2021).","journal-title":"Cell Metab."},{"key":"2326_CR274","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/s43587-023-00428-8","volume":"3","author":"C Ding","year":"2023","unstructured":"Ding, C. et al. A T(reg)-specific long noncoding RNA maintains immune-metabolic homeostasis in aging liver. Nat. Aging 3, 813\u2013828 (2023).","journal-title":"Nat. Aging"},{"key":"2326_CR275","doi-asserted-by":"publisher","first-page":"865593","DOI":"10.3389\/fimmu.2022.865593","volume":"13","author":"J Lee","year":"2022","unstructured":"Lee, J., Kim, D. & Min, B. Tissue resident Foxp3(+) regulatory T cells: sentinels and saboteurs in health and disease. Front. Immunol. 13, 865593 (2022).","journal-title":"Front. Immunol."},{"key":"2326_CR276","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard, B. G. & Langsted, A. Lipoprotein(a) and cardiovascular disease. Lancet 404, 1255\u20131264 (2024).","journal-title":"Lancet"},{"key":"2326_CR277","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3389\/fimmu.2019.02795","volume":"10","author":"CJ Albany","year":"2019","unstructured":"Albany, C. J. et al. Getting to the heart of the matter: the role of regulatory T-cells (Tregs) in cardiovascular disease (CVD) and atherosclerosis. Front. Immunol. 10, 2795 (2019).","journal-title":"Front. Immunol."},{"key":"2326_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331609","volume":"15","author":"Y Xia","year":"2024","unstructured":"Xia, Y. et al. Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets. Front. Immunol. 15, 1331609 (2024).","journal-title":"Front. Immunol."},{"key":"2326_CR279","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1097\/CM9.0000000000002875","volume":"136","author":"W Hu","year":"2023","unstructured":"Hu, W., Li, J. & Cheng, X. Regulatory T cells and cardiovascular diseases. Chin. Med. J.136, 2812\u20132823 (2023).","journal-title":"Chin. Med. J."},{"key":"2326_CR280","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1007\/s11033-021-06483-x","volume":"48","author":"R Kuan","year":"2021","unstructured":"Kuan, R., Agrawal, D. K. & Thankam, F. G. Treg cells in atherosclerosis. Mol. Biol. Rep. 48, 4897\u20134910 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"2326_CR281","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.5114\/amsad.2019.87525","volume":"4","author":"MR Yazdani","year":"2019","unstructured":"Yazdani, M. R., Khosropanah, S. & Doroudchi, M. Interleukin-17 production by CD4+CD45RO+Foxp3+ T cells in peripheral blood of patients with atherosclerosis. Arch. Med. Sci. Atheroscler. Dis. 4, e215\u2013e224 (2019).","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"2326_CR282","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni.1952","volume":"11","author":"LW Collison","year":"2010","unstructured":"Collison, L. W. et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093\u20131101 (2010).","journal-title":"Nat. Immunol."},{"key":"2326_CR283","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/jir.2021.0147","volume":"41","author":"C Ye","year":"2021","unstructured":"Ye, C., Yano, H., Workman, C. J. & Vignali, D. A. A. Interleukin-35: structure, function and its impact on immune-related diseases. J. Interferon Cytokine Res. 41, 391\u2013406 (2021).","journal-title":"J. Interferon Cytokine Res."},{"key":"2326_CR284","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1001\/jama.2023.1699","volume":"329","author":"BE Landon","year":"2023","unstructured":"Landon, B. E. et al. Differences in treatment patterns and outcomes of acute myocardial infarction for low- and high-income patients in 6 countries. JAMA 329, 1088\u20131097 (2023).","journal-title":"JAMA"},{"key":"2326_CR285","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2023.19597","volume":"330","author":"L Blue","year":"2023","unstructured":"Blue, L. et al. Effects of the million hearts model on myocardial infarctions, strokes, and medicare spending: a randomized clinical trial. JAMA 330, 1437\u20131447 (2023).","journal-title":"JAMA"},{"key":"2326_CR286","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacbts.2022.05.001","volume":"7","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. Propionate alleviates abdominal aortic aneurysm by modulating colonic regulatory t-cell expansion and recirculation. JACC Basic Transl. Sci. 7, 934\u2013947 (2022).","journal-title":"JACC Basic Transl. Sci."},{"key":"2326_CR287","doi-asserted-by":"publisher","first-page":"e152418","DOI":"10.1172\/JCI152418","volume":"132","author":"R Blanco-Dominguez","year":"2022","unstructured":"Blanco-Dominguez, R. et al. CD69 expression on regulatory T cells protects from immune damage after myocardial infarction. J. Clin. Investig. 132, e152418 (2022).","journal-title":"J. Clin. Investig."},{"key":"2326_CR288","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50806-y","volume":"15","author":"YK Alshoubaki","year":"2024","unstructured":"Alshoubaki, Y. K. et al. Tregs delivered post-myocardial infarction adopt an injury-specific phenotype promoting cardiac repair via macrophages in mice. Nat. Commun. 15, 6480 (2024).","journal-title":"Nat. Commun."},{"key":"2326_CR289","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062602","volume":"12","author":"R Sriranjan","year":"2022","unstructured":"Sriranjan, R. et al. Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial. BMJ Open 12, e062602 (2022).","journal-title":"BMJ Open"},{"key":"2326_CR290","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51353-2","volume":"15","author":"B Nayer","year":"2024","unstructured":"Nayer, B. et al. Local administration of regulatory T cells promotes tissue healing. Nat. Commun. 15, 7863 (2024).","journal-title":"Nat. Commun."},{"key":"2326_CR291","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.jaut.2022.102986","volume":"144","author":"A Stucchi","year":"2024","unstructured":"Stucchi, A., Maspes, F., Montee-Rodrigues, E. & Fousteri, G. Engineered Treg cells: the heir to the throne of immunotherapy. J. Autoimmun. 144, 102986 (2024).","journal-title":"J. Autoimmun."},{"key":"2326_CR292","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2326_CR293","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmch.2018.12.001","volume":"58","author":"K Valko","year":"2019","unstructured":"Valko, K. & Ciesla, L. Amyotrophic lateral sclerosis. Prog. Med. Chem. 58, 63\u2013117 (2019).","journal-title":"Prog. Med. Chem."},{"key":"2326_CR294","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamaneurol.2018.0043","volume":"75","author":"DR Beers","year":"2018","unstructured":"Beers, D. R., Zhao, W. & Appel, S. H. The role of regulatory T lymphocytes in amyotrophic lateral sclerosis. JAMA Neurol. 75, 656\u2013658 (2018).","journal-title":"JAMA Neurol."},{"key":"2326_CR295","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/emmm.201201544","volume":"5","author":"JS Henkel","year":"2013","unstructured":"Henkel, J. S. et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 5, 64\u201379 (2013).","journal-title":"EMBO Mol. Med."},{"key":"2326_CR296","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89530","volume":"2","author":"DR Beers","year":"2017","unstructured":"Beers, D. R. et al. ALS patients\u2019 regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2, e89530 (2017).","journal-title":"JCI Insight"},{"key":"2326_CR297","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34526-9","volume":"13","author":"S Yazdani","year":"2022","unstructured":"Yazdani, S. et al. T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression. Nat. Commun. 13, 6733 (2022).","journal-title":"Nat. Commun."},{"key":"2326_CR298","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/brain\/awr074","volume":"134","author":"DR Beers","year":"2011","unstructured":"Beers, D. R. et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134, 1293\u20131314 (2011).","journal-title":"Brain"},{"key":"2326_CR299","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamaneurol.2018.0035","volume":"75","author":"RK Sheean","year":"2018","unstructured":"Sheean, R. K. et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 75, 681\u2013689 (2018).","journal-title":"JAMA Neurol."},{"key":"2326_CR300","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08960-1","volume":"10","author":"KH Toomer","year":"2019","unstructured":"Toomer, K. H. et al. Essential and non-overlapping IL-2R\u03b1-dependent processes for thymic development and peripheral homeostasis of regulatory T cells. Nat. Commun. 10, 1037 (2019).","journal-title":"Nat. Commun."},{"key":"2326_CR301","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez, N., Woytschak, J. & Boyman, O. Interleukin-2: biology, design and application. Trends Immunol. 36, 763\u2013777 (2015).","journal-title":"Trends Immunol."},{"key":"2326_CR302","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/cei\/uxac105","volume":"211","author":"F Harris","year":"2023","unstructured":"Harris, F., Berdugo, Y. A. & Tree, T. IL-2-based approaches to Treg enhancement. Clin. Exp. Immunol. 211, 149\u2013163 (2023).","journal-title":"Clin. Exp. Immunol."},{"key":"2326_CR303","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/mt.2014.50","volume":"22","author":"S Ito","year":"2014","unstructured":"Ito, S. et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol. Ther. 22, 1388\u20131395 (2014).","journal-title":"Mol. Ther."},{"key":"2326_CR304","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol. 1, 295\u2013305 (2013).","journal-title":"Lancet Diab Endocrinol."},{"key":"2326_CR305","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/BOR.0000000000000575","volume":"31","author":"JY Humrich","year":"2019","unstructured":"Humrich, J. Y. & Riemekasten, G. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus. Curr. Opin. Rheumatol. 31, 208\u2013212 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2326_CR306","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2326_CR307","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1523\/JNEUROSCI.1815-18.2019","volume":"39","author":"SS Duffy","year":"2019","unstructured":"Duffy, S. S. et al. Regulatory T cells and their derived cytokine, interleukin-35, reduce pain in experimental autoimmune encephalomyelitis. J. Neurosci. 39, 2326\u20132346 (2019).","journal-title":"J. Neurosci."},{"key":"2326_CR308","doi-asserted-by":"crossref","unstructured":"Thonhoff, J. R. et al. Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflammation 9, e200019 (2022).","DOI":"10.1212\/NXI.0000000000200019"},{"key":"2326_CR309","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.ebiom.2020.102844","volume":"59","author":"W Camu","year":"2020","unstructured":"Camu, W. et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine 59, 102844 (2020).","journal-title":"EBioMedicine"},{"key":"2326_CR310","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab141","volume":"3","author":"I Giovannelli","year":"2021","unstructured":"Giovannelli, I. et al. Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Commun. 3, fcab141 (2021).","journal-title":"Brain Commun."},{"key":"2326_CR311","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"2326_CR312","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 388, 505\u2013517 (2016).","journal-title":"Lancet"},{"key":"2326_CR313","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fnagi.2019.00124","volume":"11","author":"L Sun","year":"2019","unstructured":"Sun, L. et al. Decreased Netrin-1 and correlated Th17\/Tregs balance disorder in A\u03b2(1-42) induced Alzheimer\u2019s disease model rats. Front. Aging Neurosci. 11, 124 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"2326_CR314","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3389\/fimmu.2018.01213","volume":"9","author":"TJ Oberstein","year":"2018","unstructured":"Oberstein, T. J. et al. Imbalance of circulating T(h)17 and regulatory T cells in Alzheimer\u2019s disease: a case control study. Front. Immunol. 9, 1213 (2018).","journal-title":"Front. Immunol."},{"key":"2326_CR315","doi-asserted-by":"publisher","first-page":"104778","DOI":"10.1016\/j.cellimm.2023.104778","volume":"393-394","author":"A Jafarzadeh","year":"2023","unstructured":"Jafarzadeh, A., Sheikhi, A., Jafarzadeh, Z. & Nemati, M. Differential roles of regulatory T cells in Alzheimer\u2019s disease. Cell Immunol. 393-394, 104778 (2023).","journal-title":"Cell Immunol."},{"key":"2326_CR316","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02308-7","volume":"18","author":"J Machhi","year":"2021","unstructured":"Machhi, J. et al. CD4+ effector T cells accelerate Alzheimer\u2019s disease in mice. J. Neuroinflammation 18, 272 (2021).","journal-title":"J. Neuroinflammation"},{"key":"2326_CR317","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/brain\/awv408","volume":"139","author":"C Dansokho","year":"2016","unstructured":"Dansokho, C. et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain 139, 1237\u20131251 (2016).","journal-title":"Brain"},{"key":"2326_CR318","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207719","volume":"35","author":"M Jung","year":"2023","unstructured":"Jung, M. et al. A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for Alzheimer\u2019s disease. Adv. Mater. 35, e2207719 (2023).","journal-title":"Adv. Mater."},{"key":"2326_CR319","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","volume":"172","author":"A Elbaz","year":"2016","unstructured":"Elbaz, A., Carcaillon, L., Kab, S. & Moisan, F. Epidemiology of Parkinson\u2019s disease. Rev. Neurol.172, 14\u201326 (2016).","journal-title":"Rev. Neurol."},{"key":"2326_CR320","unstructured":"Feigin, V. L. et al. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459-480, (2019)."},{"key":"2326_CR321","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaneurol.2016.0947","volume":"73","author":"R Savica","year":"2016","unstructured":"Savica, R. et al. Time Trends in the Incidence of Parkinson Disease. JAMA Neurol. 73, 981\u2013989 (2016).","journal-title":"JAMA Neurol."},{"key":"2326_CR322","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.bbi.2012.08.013","volume":"26","author":"ES Chung","year":"2012","unstructured":"Chung, E. S. et al. Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson\u2019s disease: role of regulatory T cells. Brain Behav. Immun. 26, 1322\u20131330 (2012).","journal-title":"Brain Behav. Immun."},{"key":"2326_CR323","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/jnr.24073","volume":"96","author":"SS Duffy","year":"2018","unstructured":"Duffy, S. S., Keating, B. A., Perera, C. J. & Moalem-Taylor, G. The role of regulatory T cells in nervous system pathologies. J. Neurosci. Res. 96, 951\u2013968 (2018).","journal-title":"J. Neurosci. Res."},{"key":"2326_CR324","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11481-019-09888-5","volume":"15","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. Treg cells attenuate neuroinflammation and protect neurons in a mouse model of Parkinson\u2019s disease. J. Neuroimmune Pharm. 15, 224\u2013237 (2020).","journal-title":"J. Neuroimmune Pharm."},{"key":"2326_CR325","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41392-023-01681-4","volume":"8","author":"CW Ip","year":"2023","unstructured":"Ip, C. W. & Wischhusen, J. Versatile guardians: regenerative regulatory T cells in Parkinson\u2019s disease rodent models. Signal Transduct. Target. Ther. 8, 430 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2326_CR326","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41531-021-00188-5","volume":"7","author":"AD Thome","year":"2021","unstructured":"Thome, A. D. et al. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson\u2019s disease. NPJ Parkinsons Dis. 7, 41 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"2326_CR327","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103380","volume":"67","author":"KE Olson","year":"2021","unstructured":"Olson, K. E. et al. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson\u2019s disease. EBioMedicine 67, 103380 (2021).","journal-title":"EBioMedicine"},{"key":"2326_CR328","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","volume":"3","author":"HE Gendelman","year":"2017","unstructured":"Gendelman, H. E. et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. NPJ Parkinsons Dis. 3, 10 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"2326_CR329","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JA Saunders","year":"2012","unstructured":"Saunders, J. A. et al. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J. Neuroimmune Pharm. 7, 927\u2013938 (2012).","journal-title":"J. Neuroimmune Pharm."},{"key":"2326_CR330","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.0901852","volume":"184","author":"AD Reynolds","year":"2010","unstructured":"Reynolds, A. D. et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson\u2019s disease. J. Immunol. 184, 2261\u20132271 (2010).","journal-title":"J. Immunol."},{"key":"2326_CR331","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2174\/1566524033479429","volume":"3","author":"T Takahashi","year":"2003","unstructured":"Takahashi, T. & Sakaguchi, S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr. Mol. Med. 3, 693\u2013706 (2003).","journal-title":"Curr. Mol. Med."},{"key":"2326_CR332","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103\u2013115 (2020).","journal-title":"Nat. Rev. Neurosci."},{"key":"2326_CR333","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrneurol.2015.123","volume":"11","author":"RA Barker","year":"2015","unstructured":"Barker, R. A., Drouin-Ouellet, J. & Parmar, M. Cell-based therapies for Parkinson disease\u2014past insights and future potential. Nat. Rev. Neurol. 11, 492\u2013503 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"2326_CR334","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/joim.12415","volume":"279","author":"O Lindvall","year":"2016","unstructured":"Lindvall, O. Clinical translation of stem cell transplantation in Parkinson\u2019s disease. J. Intern. Med. 279, 30\u201340 (2016).","journal-title":"J. Intern. Med."},{"key":"2326_CR335","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41434-019-0077-4","volume":"27","author":"SD Wenker","year":"2020","unstructured":"Wenker, S. D. & Pitossi, F. J. Cell therapy for Parkinson\u2019s disease is coming of age: current challenges and future prospects with a focus on immunomodulation. Gene Ther. 27, 6\u201314 (2020).","journal-title":"Gene Ther."},{"key":"2326_CR336","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/096368970000900205","volume":"9","author":"P Brundin","year":"2000","unstructured":"Brundin, P. et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transpl. 9, 179\u2013195 (2000).","journal-title":"Cell Transpl."},{"key":"2326_CR337","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-023-06300-4","volume":"619","author":"TY Park","year":"2023","unstructured":"Park, T. Y. et al. Co-transplantation of autologous T(reg) cells in a cell therapy for Parkinson\u2019s disease. Nature 619, 606\u2013615 (2023).","journal-title":"Nature"},{"key":"2326_CR338","doi-asserted-by":"publisher","first-page":"969633","DOI":"10.3389\/fimmu.2022.969633","volume":"13","author":"M Muckenhuber","year":"2022","unstructured":"Muckenhuber, M., Wekerle, T. & Schwarz, C. Costimulation blockade and Tregs in solid organ transplantation. Front Immunol. 13, 969633 (2022).","journal-title":"Front Immunol."},{"key":"2326_CR339","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113560","volume":"14","author":"DL Huang","year":"2023","unstructured":"Huang, D. L. et al. The immunomodulation role of Th17 and Treg in renal transplantation. Front. Immunol. 14, 1113560 (2023).","journal-title":"Front. Immunol."},{"key":"2326_CR340","doi-asserted-by":"publisher","first-page":"535012","DOI":"10.3389\/fimmu.2021.535012","volume":"12","author":"X Ni","year":"2021","unstructured":"Ni, X., Wang, Q., Gu, J. & Lu, L. Clinical and basic research progress on Treg-induced immune tolerance in liver transplantation. Front. Immunol. 12, 535012 (2021).","journal-title":"Front. Immunol."},{"key":"2326_CR341","doi-asserted-by":"publisher","first-page":"25784","DOI":"10.1073\/pnas.1910701116","volume":"116","author":"JD Fisher","year":"2019","unstructured":"Fisher, J. D. et al. Treg-inducing microparticles promote donor-specific tolerance in experimental vascularized composite allotransplantation. Proc. Natl. Acad. Sci. USA 116, 25784\u201325789 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR342","doi-asserted-by":"publisher","first-page":"746889","DOI":"10.3389\/fimmu.2022.746889","volume":"13","author":"T Juneja","year":"2022","unstructured":"Juneja, T., Kazmi, M., Mellace, M. & Saidi, R. F. Utilization of Treg cells in solid organ transplantation. Front. Immunol. 13, 746889 (2022).","journal-title":"Front. Immunol."},{"key":"2326_CR343","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1074\/jbc.M109.047423","volume":"285","author":"M Mandapathil","year":"2010","unstructured":"Mandapathil, M. et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 285, 7176\u20137186 (2010).","journal-title":"J. Biol. Chem."},{"key":"2326_CR344","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36924-z","volume":"14","author":"Y Yamada","year":"2023","unstructured":"Yamada, Y. et al. Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice. Nat. Commun. 14, 1383 (2023).","journal-title":"Nat. Commun."},{"key":"2326_CR345","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/ajt.17063","volume":"22","author":"JC Wagner","year":"2022","unstructured":"Wagner, J. C. et al. Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival. Am. J. Transpl. 22, 2237\u20132245 (2022).","journal-title":"Am. J. Transpl."},{"key":"2326_CR346","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.28459","volume":"64","author":"S Todo","year":"2016","unstructured":"Todo, S. et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology 64, 632\u2013643 (2016).","journal-title":"Hepatology"},{"key":"2326_CR347","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2337\/db19-0061","volume":"69","author":"C Cabello-Kindelan","year":"2020","unstructured":"Cabello-Kindelan, C. et al. Immunomodulation followed by antigen-specific T(reg) infusion controls islet autoimmunity. Diabetes 69, 215\u2013227 (2020).","journal-title":"Diabetes"},{"key":"2326_CR348","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI41072","volume":"120","author":"K Matsuoka","year":"2010","unstructured":"Matsuoka, K. et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Investig. 120, 1479\u20131493 (2010).","journal-title":"J. Clin. Investig."},{"key":"2326_CR349","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.697854","volume":"12","author":"WW Guo","year":"2021","unstructured":"Guo, W. W. et al. Regulatory T cells in GVHD therapy. Front. Immunol. 12, 697854 (2021).","journal-title":"Front. Immunol."},{"key":"2326_CR350","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","volume":"20","author":"AA Kennedy-Nasser","year":"2014","unstructured":"Kennedy-Nasser, A. A. et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin. Cancer Res. 20, 2215\u20132225 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2326_CR351","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2022018440","volume":"141","author":"TL Ramos","year":"2023","unstructured":"Ramos, T. L. et al. Prevention of acute GVHD using an orthogonal IL-2\/IL-2Rbeta system to selectively expand regulatory T cells in vivo. Blood 141, 1337\u20131352 (2023).","journal-title":"Blood"},{"key":"2326_CR352","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood.2022017982","volume":"141","author":"JK Lohmeyer","year":"2023","unstructured":"Lohmeyer, J. K. et al. Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD. Blood 141, 1755\u20131767 (2023).","journal-title":"Blood"},{"key":"2326_CR353","first-page":"129","volume":"109","author":"A Thiolat","year":"2024","unstructured":"Thiolat, A. et al. Treg-targeted IL-2\/anti-IL-2 complex controls graft-versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation. Haematologica 109, 129\u2013142 (2024).","journal-title":"Haematologica"},{"key":"2326_CR354","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.it.2019.11.005","volume":"41","author":"KL Hippen","year":"2020","unstructured":"Hippen, K. L. et al. Distinct regulatory and effector T cell metabolic demands during graft-versus-host disease. Trends Immunol. 41, 77\u201391 (2020).","journal-title":"Trends Immunol."},{"key":"2326_CR355","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1716","volume":"14","author":"SJ Yang","year":"2022","unstructured":"Yang, S. J. et al. Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models. Sci. Transl. Med. 14, eabn1716 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2326_CR356","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","volume":"44","author":"S Bittner","year":"2023","unstructured":"Bittner, S., Hehlgans, T. & Feuerer, M. Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond. Trends Immunol. 44, 468\u2013483 (2023).","journal-title":"Trends Immunol."},{"key":"2326_CR357","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541\u2013566 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"2326_CR358","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2012.00317","volume":"3","author":"SP Cobbold","year":"2012","unstructured":"Cobbold, S. P. & Li, X. C. Translating tolerogenic therapies to the clinic\u2014where do we stand and what are the barriers?. Front Immunol. 3, 317 (2012).","journal-title":"Front Immunol."},{"key":"2326_CR359","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2326_CR360","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41573-020-00116-x","volume":"20","author":"NM Edner","year":"2021","unstructured":"Edner, N. M., Carlesso, G., Rush, J. S. & Walker, L. S. K. Publisher Correction: Targeting co-stimulatory molecules in autoimmune disease. Nat. Rev. Drug Discov. 20, 82 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2326_CR361","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken, K. E. & Wherry, E. J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265\u2013276 (2015).","journal-title":"Trends Immunol."},{"key":"2326_CR362","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","volume":"28","author":"M Croft","year":"2010","unstructured":"Croft, M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57\u201378 (2010).","journal-title":"Annu. Rev. Immunol."},{"key":"2326_CR363","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2006-05-025460","volume":"109","author":"D Golshayan","year":"2007","unstructured":"Golshayan, D. et al. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 109, 827\u2013835 (2007).","journal-title":"Blood"},{"key":"2326_CR364","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.997376","volume":"14","author":"JA Pereira","year":"2023","unstructured":"Pereira, J. A. et al. PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis. Front. Immunol. 14, 997376 (2023).","journal-title":"Front. Immunol."},{"key":"2326_CR365","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni, F. et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184, 3998\u20134015 e3919 (2021).","journal-title":"Cell"},{"key":"2326_CR366","doi-asserted-by":"crossref","unstructured":"Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 118, e2023739118 (2021).","DOI":"10.1073\/pnas.2023739118"},{"key":"2326_CR367","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi, R. et al. CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature 591, 652\u2013658 (2021).","journal-title":"Nature"},{"key":"2326_CR368","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med."},{"key":"2326_CR369","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1073\/pnas.1812186116","volume":"116","author":"D Ha","year":"2019","unstructured":"Ha, D. et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc. Natl. Acad. Sci. USA 116, 609\u2013618 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR370","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30143-8","volume":"13","author":"P John","year":"2022","unstructured":"John, P. et al. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. Nat. Commun. 13, 2506 (2022).","journal-title":"Nat. Commun."},{"key":"2326_CR371","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/2326-6066.CIR-23-0389","volume":"12","author":"DA Knorr","year":"2024","unstructured":"Knorr, D. A. et al. FcgammaRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer Immunol. Res. 12, 322\u2013333 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR372","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","volume":"8","author":"F Shan","year":"2022","unstructured":"Shan, F. et al. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer 8, 944\u2013961 (2022).","journal-title":"Trends Cancer"},{"key":"2326_CR373","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14712598.2017.1333595","volume":"17","author":"RL Crepeau","year":"2017","unstructured":"Crepeau, R. L. & Ford, M. L. Challenges and opportunities in targeting the CD28\/CTLA-4 pathway in transplantation and autoimmunity. Expert Opin. Biol. Ther. 17, 1001\u20131012 (2017).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2326_CR374","doi-asserted-by":"crossref","unstructured":"Bano, A. et al. CD28 (null) CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection. F1000Research 8, F1000-aculty (2019).","DOI":"10.12688\/f1000research.17119.1"},{"key":"2326_CR375","doi-asserted-by":"crossref","unstructured":"Liu, D., Badell, I. R. & Ford, M. L. Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival. JCI Insight. 3, e96378 (2018).","DOI":"10.1172\/jci.insight.96378"},{"key":"2326_CR376","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","volume":"14","author":"MM Hossen","year":"2023","unstructured":"Hossen, M. M. et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front. Immunol. 14, 1198365 (2023).","journal-title":"Front. Immunol."},{"key":"2326_CR377","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope, A. P. et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403, 838\u2013849 (2024).","journal-title":"Lancet"},{"key":"2326_CR378","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1681\/ASN.2021050628","volume":"32","author":"K Budde","year":"2021","unstructured":"Budde, K. et al. Conversion from calcineurin inhibitor\u2014to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial. J. Am. Soc. Nephrol. 32, 3252\u20133264 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2326_CR379","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"2326_CR380","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","volume":"15","author":"S Champiat","year":"2018","unstructured":"Champiat, S. et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat. Rev. Clin. Oncol. 15, 748\u2013762 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2326_CR381","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/HEP.0000000000000320","volume":"78","author":"Q Wu","year":"2023","unstructured":"Wu, Q. et al. Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Hepatology 78, 1402\u20131417 (2023).","journal-title":"Hepatology"},{"key":"2326_CR382","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40, 201\u2013218 e209 (2022).","journal-title":"Cancer Cell"},{"key":"2326_CR383","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk, M. et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci. Immunol. 8, eabn6173 (2023).","journal-title":"Sci. Immunol."},{"key":"2326_CR384","doi-asserted-by":"publisher","first-page":"925","DOI":"10.5114\/ada.2021.112274","volume":"38","author":"M Adamczyk","year":"2021","unstructured":"Adamczyk, M. & Krasowska, D. PD1\/PD-L1 pathway in psoriasis and psoriatic arthritis: a review. Postepy Dermatol. Alergol. 38, 925\u2013930 (2021).","journal-title":"Postepy Dermatol. Alergol."},{"key":"2326_CR385","doi-asserted-by":"crossref","unstructured":"Borges, T. J. et al. Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. JCI Insight. 6, e142909 (2021).","DOI":"10.1172\/jci.insight.142909"},{"key":"2326_CR386","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109051","volume":"110","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. Blockade of PD-1\/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease. Int. Immunopharmacol. 110, 109051 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"2326_CR387","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","volume":"591","author":"SA Lim","year":"2021","unstructured":"Lim, S. A. et al. Lipid signalling enforces functional specialization of T(reg) cells in tumours. Nature 591, 306\u2013311 (2021).","journal-title":"Nature"},{"key":"2326_CR388","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","volume":"18","author":"LMR Ferreira","year":"2019","unstructured":"Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749\u2013769 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2326_CR389","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature 627, 646\u2013655 (2024).","journal-title":"Nature"},{"key":"2326_CR390","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911919","volume":"13","author":"C Yue","year":"2022","unstructured":"Yue, C. et al. TIGIT as a promising therapeutic target in autoimmune diseases. Front. Immunol. 13, 911919 (2022).","journal-title":"Front. Immunol."},{"key":"2326_CR391","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121517","volume":"285","author":"Q Guo","year":"2022","unstructured":"Guo, Q. et al. Engineered PD-1\/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell\/Treg balance and alleviate systemic lupus erythematosus. Biomaterials 285, 121517 (2022).","journal-title":"Biomaterials"},{"key":"2326_CR392","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-23-0258","volume":"29","author":"M Heiduk","year":"2023","unstructured":"Heiduk, M. et al. TIGIT expression delineates T-cell populations with distinct functional and prognostic impact in pancreatic cancer. Clin. Cancer Res. 29, 2638\u20132650 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2326_CR393","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-20-0575","volume":"26","author":"JM Chauvin","year":"2020","unstructured":"Chauvin, J. M. et al. IL15 Stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. Clin. Cancer Res. 26, 5520\u20135533 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2326_CR394","doi-asserted-by":"crossref","unstructured":"Fourcade, J. et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 3, e121157 (2018).","DOI":"10.1172\/jci.insight.121157"},{"key":"2326_CR395","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32\u201342 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR396","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"Arce","year":"2018","unstructured":"Arce et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33, 649\u2013663 e644 (2018).","journal-title":"Cancer Cell"},{"key":"2326_CR397","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3390\/cells12162066","volume":"12","author":"R Gedaly","year":"2023","unstructured":"Gedaly, R. et al. Metabolic disruption induced by mTOR signaling pathway inhibition in regulatory T-cell expansion for clinical application. Cells 12, 2066 (2023).","journal-title":"Cells"},{"key":"2326_CR398","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.23.01363","volume":"42","author":"CM Rudin","year":"2024","unstructured":"Rudin, C. M. et al. SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer. J. Clin. Oncol. 42, 324\u2013335 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2326_CR399","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41375-021-01301-6","volume":"36","author":"J Bae","year":"2022","unstructured":"Bae, J. et al. Targeting LAG3\/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia 36, 138\u2013154 (2022).","journal-title":"Leukemia"},{"key":"2326_CR400","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jaccao.2022.09.005","volume":"4","author":"M Mulholland","year":"2022","unstructured":"Mulholland, M. et al. LAG3 Regulates T cell activation and plaque infiltration in atherosclerotic mice. JACC CardioOncol 4, 635\u2013645 (2022).","journal-title":"JACC CardioOncol"},{"key":"2326_CR401","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"2326_CR402","doi-asserted-by":"crossref","unstructured":"Chocarro, L. et al. Understanding LAG-3 signaling. Int. J. Mol. Sci. 22, 5282 (2021).","DOI":"10.3390\/ijms22105282"},{"key":"2326_CR403","doi-asserted-by":"publisher","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","volume":"13","author":"JL Huo","year":"2022","unstructured":"Huo, J. L. et al. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front. Immunol. 13, 956090 (2022).","journal-title":"Front. Immunol."},{"key":"2326_CR404","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41590-022-01210-5","volume":"23","author":"S Grebinoski","year":"2022","unstructured":"Grebinoski, S. et al. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat. Immunol. 23, 868\u2013877 (2022).","journal-title":"Nat. Immunol."},{"key":"2326_CR405","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4049\/jimmunol.2100850","volume":"208","author":"BE Jones","year":"2022","unstructured":"Jones, B. E. et al. Fewer LAG-3(+) T cells in relapsing-remitting multiple sclerosis and type 1 diabetes. J. Immunol. 208, 594\u2013602 (2022).","journal-title":"J. Immunol."},{"key":"2326_CR406","doi-asserted-by":"publisher","first-page":"15244","DOI":"10.3390\/ijms232315244","volume":"23","author":"E Garcia-Martin","year":"2022","unstructured":"Garcia-Martin, E. et al. Association between LAG3\/CD4 genes variants and risk for multiple sclerosis. Int J. Mol. Sci. 23, 15244 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"2326_CR407","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50007-7","volume":"15","author":"S Saevarsdottir","year":"2024","unstructured":"Saevarsdottir, S. et al. Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease. Nat. Commun. 15, 5748 (2024).","journal-title":"Nat. Commun."},{"key":"2326_CR408","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2337\/db22-0482","volume":"72","author":"FM Qureshi","year":"2023","unstructured":"Qureshi, F. M. et al. Immunotherapy with low-dose IL-2\/CD25 prevents beta-cell dysfunction and dysglycemia in prediabetic NOD mice. Diabetes 72, 769\u2013780 (2023).","journal-title":"Diabetes"},{"key":"2326_CR409","doi-asserted-by":"crossref","unstructured":"Ren, Z. et al. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. J. Clin. Investig. 132, e153604 (2022).","DOI":"10.1172\/JCI153604"},{"key":"2326_CR410","doi-asserted-by":"crossref","unstructured":"Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).","DOI":"10.1016\/j.jtauto.2021.100103"},{"key":"2326_CR411","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119132","volume":"284","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh, V. et al. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 284, 119132 (2021).","journal-title":"Life Sci."},{"key":"2326_CR412","doi-asserted-by":"crossref","unstructured":"Zammarchi, F. et al. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J. Immunother. Cancer. 8, e000860 (2020).","DOI":"10.1136\/jitc-2020-000860"},{"key":"2326_CR413","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/d41573-020-00206-w","volume":"20","author":"MT Villanueva","year":"2021","unstructured":"Villanueva, M. T. Anti-CD25 antibody tips the T cell balance. Nat. Rev. Drug Discov. 20, 18 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2326_CR414","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"Arce","year":"2017","unstructured":"Arce et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577\u2013586 (2017).","journal-title":"Immunity"},{"key":"2326_CR415","doi-asserted-by":"publisher","first-page":"e000738","DOI":"10.1136\/esmoopen-2020-000738","volume":"4","author":"G Buzzatti","year":"2020","unstructured":"Buzzatti, G., Dellepiane, C. & Del Mastro, L. New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open 4, e000738 (2020).","journal-title":"ESMO Open"},{"key":"2326_CR416","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/1756-185X.12451","volume":"19","author":"J Sun","year":"2016","unstructured":"Sun, J. et al. Aberrant GITR expression on different T cell subsets and the regulation by glucocorticoid in systemic lupus erythematosus. Int. J. Rheum. Dis. 19, 199\u2013204 (2016).","journal-title":"Int. J. Rheum. Dis."},{"key":"2326_CR417","first-page":"702","volume":"35","author":"M Hilaire","year":"2019","unstructured":"Hilaire, M. & Aubert, N. Boosting Treg activity by TNFR2 and GITR agonists: new therapeutic approaches for autoimmune diseases. Med. Sci.35, 702\u2013705 (2019).","journal-title":"Med. Sci."},{"key":"2326_CR418","doi-asserted-by":"publisher","first-page":"588682","DOI":"10.3389\/fimmu.2020.588682","volume":"11","author":"J Tian","year":"2020","unstructured":"Tian, J., Zhang, B., Rui, K. & Wang, S. The role of GITR\/GITRL interaction in autoimmune diseases. Front Immunol. 11, 588682 (2020).","journal-title":"Front Immunol."},{"key":"2326_CR419","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.4049\/jimmunol.172.8.4686","volume":"172","author":"AP Kohm","year":"2004","unstructured":"Kohm, A. P., Williams, J. S. & Miller, S. D. Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis. J. Immunol. 172, 4686\u20134690 (2004).","journal-title":"J. Immunol."},{"key":"2326_CR420","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120648","volume":"269","author":"Q Sun","year":"2021","unstructured":"Sun, Q. et al. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials 269, 120648 (2021).","journal-title":"Biomaterials"},{"key":"2326_CR421","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2326-6066.CIR-13-0086","volume":"1","author":"DA Schaer","year":"2013","unstructured":"Schaer, D. A. et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol. Res. 1, 320\u2013331 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR422","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","volume":"25","author":"R Zappasodi","year":"2019","unstructured":"Zappasodi, R. et al. Rational design of anti-GITR-based combination immunotherapy. Nat. Med. 25, 759\u2013766 (2019).","journal-title":"Nat. Med."},{"key":"2326_CR423","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01259-3","volume":"15","author":"A Sathe","year":"2023","unstructured":"Sathe, A. et al. GITR and TIGIT immunotherapy provokes divergent multi-cellular responses in the tumor microenvironment of gastrointestinal cancers. Genome Med. 15, 100 (2023).","journal-title":"Genome Med."},{"key":"2326_CR424","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105529","volume":"25","author":"S Ke","year":"2022","unstructured":"Ke, S. et al. High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer. iScience 25, 105529 (2022).","journal-title":"iScience"},{"key":"2326_CR425","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/psp4.12925","volume":"12","author":"Y Ji","year":"2023","unstructured":"Ji, Y. et al. Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment. CPT Pharmacomet. Syst. Pharm. 12, 413\u2013424 (2023).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"2326_CR426","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","volume":"44","author":"LK Ward-Kavanagh","year":"2016","unstructured":"Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R. & Ware, C. F. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 44, 1005\u20131019 (2016).","journal-title":"Immunity"},{"key":"2326_CR427","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/cmi.2018.8","volume":"16","author":"P Kumar","year":"2019","unstructured":"Kumar, P. et al. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell. Mol. Immunol. 16, 138\u2013153 (2019).","journal-title":"Cell. Mol. Immunol."},{"key":"2326_CR428","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/annrheumdis-2019-215195","volume":"78","author":"I Kurata","year":"2019","unstructured":"Kurata, I. et al. Potential involvement of OX40 in the regulation of autoantibody sialylation in arthritis. Ann. Rheum. Dis. 78, 1488\u20131496 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2326_CR429","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4337399","volume":"2022","author":"X Zhou","year":"2022","unstructured":"Zhou, X. et al. Clinical significance of OX40 and OX40 ligand in the peripheral blood of patients with myasthenia gravis. J. Immunol. Res. 2022, 4337399 (2022).","journal-title":"J. Immunol. Res."},{"key":"2326_CR430","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jid.2022.11.009","volume":"143","author":"H Iriki","year":"2023","unstructured":"Iriki, H., Takahashi, H. & Amagai, M. Diverse role of OX40 on T cells as a therapeutic target for skin diseases. J. Investig. Dermatol. 143, 545\u2013553 (2023).","journal-title":"J. Investig. Dermatol."},{"key":"2326_CR431","doi-asserted-by":"publisher","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","volume":"115","author":"I Pacella","year":"2018","unstructured":"Pacella, I. et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc. Natl. Acad. Sci. USA 115, E6546\u2013E6555 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR432","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/1535-7163.MCT-17-0200","volume":"17","author":"MD Oberst","year":"2018","unstructured":"Oberst, M. D. et al. Potent immune modulation by MEDI6383, an engineered human OX40 ligand IgG4P Fc fusion protein. Mol. Cancer Ther. 17, 1024\u20131038 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2326_CR433","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cncr.35063","volume":"130","author":"A Knisely","year":"2024","unstructured":"Knisely, A. et al. Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130, 400\u2013409 (2024).","journal-title":"Cancer"},{"key":"2326_CR434","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1211759","volume":"13","author":"S Liang","year":"2023","unstructured":"Liang, S. et al. BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy. Front. Oncol. 13, 1211759 (2023).","journal-title":"Front. Oncol."},{"key":"2326_CR435","doi-asserted-by":"publisher","first-page":"e004235","DOI":"10.1136\/jitc-2021-004235","volume":"10","author":"EJ Davis","year":"2022","unstructured":"Davis, E. J. et al. First-in-human phase I\/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. J. Immunother. Cancer 10, e004235 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2326_CR436","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21383-1","volume":"12","author":"R Duhen","year":"2021","unstructured":"Duhen, R. et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat. Commun. 12, 1047 (2021).","journal-title":"Nat. Commun."},{"key":"2326_CR437","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1084\/jem.20050855","volume":"202","author":"B Knoechel","year":"2005","unstructured":"Knoechel, B. et al. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202, 1375\u20131386 (2005).","journal-title":"J. Exp. Med."},{"key":"2326_CR438","doi-asserted-by":"crossref","unstructured":"Alves Costa Silva, C., Facchinetti, F., Routy, B. & Derosa, L. New pathways in immune stimulation: targeting OX40. ESMO Open. 5, e000573 (2020).","DOI":"10.1136\/esmoopen-2019-000573"},{"key":"2326_CR439","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20040179","volume":"199","author":"AE Herman","year":"2004","unstructured":"Herman, A. E., Freeman, G. J., Mathis, D. & Benoist, C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199, 1479\u20131489 (2004).","journal-title":"J. Exp. Med."},{"key":"2326_CR440","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.4049\/jimmunol.1801266","volume":"202","author":"AE Landuyt","year":"2019","unstructured":"Landuyt, A. E. et al. Cutting edge: ICOS-deficient regulatory T cells display normal induction of Il10 but readily downregulate expression of Foxp3. J. Immunol. 202, 1039\u20131044 (2019).","journal-title":"J. Immunol."},{"key":"2326_CR441","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jaci.2011.08.009","volume":"129","author":"GS Whitehead","year":"2012","unstructured":"Whitehead, G. S. et al. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J. Allergy Clin. Immunol. 129, 207\u2013215 (2012). e201-205.","journal-title":"J. Allergy Clin. Immunol."},{"key":"2326_CR442","doi-asserted-by":"publisher","first-page":"701515","DOI":"10.3389\/fimmu.2021.701515","volume":"12","author":"DY Li","year":"2021","unstructured":"Li, D. Y. & Xiong, X. Z. Corrigendum: ICOS+ Tregs: a functional subset of tregs in immune diseases. Front Immunol. 12, 701515 (2021).","journal-title":"Front Immunol."},{"key":"2326_CR443","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud, M. et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat. Rev. 120, 102614 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"2326_CR444","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/0008-5472.CAN-11-1138","volume":"71","author":"T Fu","year":"2011","unstructured":"Fu, T., He, Q. & Sharma, P. The ICOS\/ICOSL pathway is required for optimal antitumor responses mediated by anti\u2013CTLA-4 therapy. Cancer Res. 71, 5445\u20135454 (2011).","journal-title":"Cancer Res."},{"key":"2326_CR445","doi-asserted-by":"publisher","first-page":"e202201615","DOI":"10.26508\/lsa.202201615","volume":"6","author":"V Panneton","year":"2023","unstructured":"Panneton, V. et al. ICOS costimulation is indispensable for the differentiation of T follicular regulatory cells. Life Sci. Alliance 6, e202201615 (2023).","journal-title":"Life Sci. Alliance"},{"key":"2326_CR446","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1158\/2326-6066.CIR-20-0034","volume":"8","author":"RCA Sainson","year":"2020","unstructured":"Sainson, R. C. A. et al. An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression. Cancer Immunol. Res. 8, 1568\u20131582 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2326_CR447","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","volume":"78","author":"TB Shabaneh","year":"2018","unstructured":"Shabaneh, T. B. et al. Oncogenic BRAF(V600E) governs regulatory T-cell recruitment during melanoma tumorigenesis. Cancer Res. 78, 5038\u20135049 (2018).","journal-title":"Cancer Res."},{"key":"2326_CR448","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto, K. et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28, 1591\u20131598 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2326_CR449","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms21218412","volume":"21","author":"J Korbecki","year":"2020","unstructured":"Korbecki, J. et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int. J. Mol. Sci. 21, 8412 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2326_CR450","doi-asserted-by":"publisher","first-page":"e000764","DOI":"10.1136\/jitc-2020-000764","volume":"8","author":"LA Marshall","year":"2020","unstructured":"Marshall, L. A. et al. Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4. J. Immunother. Cancer 8, e000764 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2326_CR451","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","volume":"45","author":"G Plitas","year":"2016","unstructured":"Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122\u20131134 (2016).","journal-title":"Immunity"},{"key":"2326_CR452","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1158\/0008-5472.CAN-20-3585","volume":"81","author":"JR Campbell","year":"2021","unstructured":"Campbell, J. R. et al. Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models. Cancer Res. 81, 2983\u20132994 (2021).","journal-title":"Cancer Res."},{"key":"2326_CR453","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1021\/acs.jmedchem.3c00030","volume":"66","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. Discovery of a potent and selective CCR8 small molecular antagonist IPG7236 for the treatment of cancer. J. Med. Chem. 66, 4548\u20134564 (2023).","journal-title":"J. Med. Chem."},{"key":"2326_CR454","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene, A. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226\u2013230 (2011).","journal-title":"Nature"},{"key":"2326_CR455","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619932","volume":"12","author":"Z Hui","year":"2021","unstructured":"Hui, Z. et al. Single-cell sequencing reveals the transcriptome and TCR characteristics of pTregs and in vitro expanded iTregs. Front Immunol. 12, 619932 (2021).","journal-title":"Front Immunol."},{"key":"2326_CR456","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-981-15-6407-9_6","volume":"1278","author":"JA Bellanti","year":"2021","unstructured":"Bellanti, J. A. & Li, D. Treg cells and epigenetic regulation. Adv. Exp. Med. Biol. 1278, 95\u2013114 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2326_CR457","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1084\/jem.20190550","volume":"216","author":"X Sun","year":"2019","unstructured":"Sun, X. et al. TGF-beta signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity. J. Exp. Med. 216, 2819\u20132837 (2019).","journal-title":"J. Exp. Med."},{"key":"2326_CR458","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01007-7","volume":"13","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. UHRF1 downregulation promotes T follicular helper cell differentiation by increasing BCL6 expression in SLE. Clin. Epigenetics 13, 31 (2021).","journal-title":"Clin. Epigenetics"},{"key":"2326_CR459","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","volume":"42","author":"M DuPage","year":"2015","unstructured":"DuPage, M. et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42, 227\u2013238 (2015).","journal-title":"Immunity"},{"key":"2326_CR460","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 23, 3262\u20133274 (2018).","journal-title":"Cell Rep."},{"key":"2326_CR461","doi-asserted-by":"crossref","unstructured":"Lee, J. C. et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci. Immunol. 5, eaba0759 (2020).","DOI":"10.1126\/sciimmunol.aba0759"},{"key":"2326_CR462","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10555-024-10167-w","volume":"43","author":"V Singh","year":"2024","unstructured":"Singh, V. et al. Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy. Cancer Metastasis Rev. 43, 175\u2013195 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"2326_CR463","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami, S. et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Investig. 128, 3813\u20133818 (2018).","journal-title":"J. Clin. Investig."},{"key":"2326_CR464","doi-asserted-by":"publisher","first-page":"909816","DOI":"10.3389\/fimmu.2022.909816","volume":"13","author":"LM Christensen","year":"2022","unstructured":"Christensen, L. M. & Hancock, W. W. Nuclear coregulatory complexes in Tregs as targets to promote anticancer immune responses. Front. Immunol. 13, 909816 (2022).","journal-title":"Front. Immunol."},{"key":"2326_CR465","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1210\/clinem\/dgab526","volume":"106","author":"P Sacristan-Gomez","year":"2021","unstructured":"Sacristan-Gomez, P. et al. Analysis of expression of different histone deacetylases in autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 106, 3213\u20133227 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2326_CR466","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","volume":"117","author":"D Buglio","year":"2011","unstructured":"Buglio, D. et al. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 117, 2910\u20132917 (2011).","journal-title":"Blood"},{"key":"2326_CR467","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1172\/JCI77088","volume":"125","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. FOXP3+ regulatory T cell development and function require histone\/protein deacetylase 3. J. Clin. Investig. 125, 1111\u20131123 (2015).","journal-title":"J. Clin. Investig."},{"key":"2326_CR468","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. Complementary roles of GCN5 and PCAF in Foxp3+ T-regulatory cells. Cancers 11, 554 (2019).","DOI":"10.3390\/cancers11040554"},{"key":"2326_CR469","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1021\/acsptsci.4c00358","volume":"7","author":"B Wu","year":"2024","unstructured":"Wu, B. et al. A novel liver cancer-selective histone deacetylase inhibitor is effective against hepatocellular carcinoma and induces durable responses with immunotherapy. ACS Pharm. Transl. Sci. 7, 3155\u20133169 (2024).","journal-title":"ACS Pharm. Transl. Sci."},{"key":"2326_CR470","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","volume":"13","author":"R Tao","year":"2007","unstructured":"Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299\u20131307 (2007).","journal-title":"Nat. Med."},{"key":"2326_CR471","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1128\/MCB.00919-14","volume":"34","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Two histone\/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function. Mol. Cell. Biol. 34, 3993\u20134007 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"2326_CR472","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.celrep.2019.03.008","volume":"27","author":"DE de Almeida Nagata","year":"2019","unstructured":"de Almeida Nagata, D. E. et al. Regulation of tumor-associated myeloid cell activity by CBP\/EP300 bromodomain modulation of H3K27 acetylation. Cell Rep. 27, 269\u2013281.e264 (2019).","journal-title":"Cell Rep."},{"key":"2326_CR473","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nature16141","volume":"528","author":"Y Feng","year":"2015","unstructured":"Feng, Y. et al. A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature 528, 132\u2013136 (2015).","journal-title":"Nature"},{"key":"2326_CR474","doi-asserted-by":"publisher","first-page":"104220","DOI":"10.1016\/j.cellimm.2020.104220","volume":"358","author":"I Rosado-Sanchez","year":"2020","unstructured":"Rosado-Sanchez, I. & Levings, M. K. Building a CAR-Treg: going from the basic to the luxury model. Cell Immunol. 358, 104220 (2020).","journal-title":"Cell Immunol."},{"key":"2326_CR475","doi-asserted-by":"publisher","first-page":"104173","DOI":"10.1016\/j.cellimm.2020.104173","volume":"355","author":"MD Mannie","year":"2020","unstructured":"Mannie, M. D., DeOca, K. B., Bastian, A. G. & Moorman, C. D. Tolerogenic vaccines: targeting the antigenic and cytokine niches of FOXP3(+) regulatory T cells. Cell Immunol. 355, 104173 (2020).","journal-title":"Cell Immunol."},{"key":"2326_CR476","doi-asserted-by":"publisher","first-page":"104193","DOI":"10.1016\/j.cellimm.2020.104193","volume":"356","author":"J Rana","year":"2020","unstructured":"Rana, J. & Biswas, M. Regulatory T cell therapy: current and future design perspectives. Cell Immunol. 356, 104193 (2020).","journal-title":"Cell Immunol."},{"key":"2326_CR477","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","volume":"10","author":"M Arjomandnejad","year":"2022","unstructured":"Arjomandnejad, M., Kopec, A. L. & Keeler, A. M. CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines 10, 287 (2022).","journal-title":"Biomedicines"},{"key":"2326_CR478","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.tibtech.2019.12.009","volume":"38","author":"E Fritsche","year":"2020","unstructured":"Fritsche, E., Volk, H. D., Reinke, P. & Abou-El-Enein, M. Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy. Trends Biotechnol. 38, 1099\u20131112 (2020).","journal-title":"Trends Biotechnol."},{"key":"2326_CR479","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","volume":"28","author":"Z Good","year":"2022","unstructured":"Good, Z. et al. Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860\u20131871 (2022).","journal-title":"Nat. Med."},{"key":"2326_CR480","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"2326_CR481","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","volume":"201","author":"AH Zhang","year":"2018","unstructured":"Zhang, A. H., Yoon, J., Kim, Y. C. & Scott, D. W. Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells. J. Immunol. 201, 1434\u20131441 (2018).","journal-title":"J. Immunol."},{"key":"2326_CR482","doi-asserted-by":"publisher","first-page":"1509956","DOI":"10.3389\/fimmu.2024.1509956","volume":"15","author":"Y Bulliard","year":"2024","unstructured":"Bulliard, Y. et al. From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. Front. Immunol. 15, 1509956 (2024).","journal-title":"Front. Immunol."},{"key":"2326_CR483","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","volume":"8","author":"J Skuljec","year":"2017","unstructured":"Skuljec, J. et al. Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma. Front. Immunol. 8, 1125 (2017).","journal-title":"Front. Immunol."},{"key":"2326_CR484","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12015-023-10668-1","volume":"20","author":"V Mohammadi","year":"2024","unstructured":"Mohammadi, V. et al. Chimeric antigen receptor (CAR)-based cell therapy for type 1 diabetes mellitus (T1DM); current progress and future approaches. Stem Cell Rev. Rep. 20, 585\u2013600 (2024).","journal-title":"Stem Cell Rev. Rep."},{"key":"2326_CR485","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03262-w","volume":"21","author":"J Frikeche","year":"2024","unstructured":"Frikeche, J. et al. MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis. J. Neuroinflammation 21, 268 (2024).","journal-title":"J. Neuroinflammation"},{"key":"2326_CR486","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01518-8","volume":"21","author":"SW Wang","year":"2022","unstructured":"Wang, S. W. et al. Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Mol. Cancer 21, 57 (2022).","journal-title":"Mol. Cancer"},{"key":"2326_CR487","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4049\/jimmunol.2200411","volume":"211","author":"N Zhai","year":"2023","unstructured":"Zhai, N. et al. Lack of IFN-gamma receptor signaling inhibits graft-versus-host disease by potentiating regulatory T cell expansion and conversion. J. Immunol. 211, 885\u2013894 (2023).","journal-title":"J. Immunol."},{"key":"2326_CR488","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","volume":"29","author":"X Chen","year":"2024","unstructured":"Chen, X., Zhong, S., Zhan, Y. & Zhang, X. CRISPR-Cas9 applications in T cells and adoptive T cell therapies. Cell Mol. Biol. Lett. 29, 52 (2024).","journal-title":"Cell Mol. Biol. Lett."},{"key":"2326_CR489","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.655122","volume":"12","author":"L Van Zeebroeck","year":"2021","unstructured":"Van Zeebroeck, L. et al. Fast and efficient genome editing of human FOXP3(+) regulatory T cells. Front. Immunol. 12, 655122 (2021).","journal-title":"Front. Immunol."},{"key":"2326_CR490","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","volume":"41","author":"A Obradovic","year":"2023","unstructured":"Obradovic, A. et al. Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators. Cancer Cell 41, 933\u2013949 e911 (2023).","journal-title":"Cancer Cell"},{"key":"2326_CR491","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6822","volume":"15","author":"S Borna","year":"2023","unstructured":"Borna, S. et al. Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients with FOXP3 mutations. Sci. Transl. Med. 15, eadg6822 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2326_CR492","doi-asserted-by":"crossref","unstructured":"Tang, N. et al. TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, e133977 (2020).","DOI":"10.1172\/jci.insight.133977"},{"key":"2326_CR493","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3389\/fonc.2020.01696","volume":"10","author":"H Tian","year":"2020","unstructured":"Tian, H., Lyu, Y., Yang, Y. G. & Hu, Z. Humanized Rodent Models for Cancer Research. Front Oncol. 10, 1696 (2020).","journal-title":"Front Oncol."},{"key":"2326_CR494","doi-asserted-by":"crossref","unstructured":"Cao, Y. et al. Integrative analysis from multi-center studies identifies a weighted gene co-expression network analysis-based Tregs signature in ovarian cancer. Environ. Toxicol. 39, 736\u2013750 (2023).","DOI":"10.1002\/tox.23948"},{"key":"2326_CR495","doi-asserted-by":"publisher","first-page":"674467","DOI":"10.3389\/fcell.2021.674467","volume":"9","author":"X Ou","year":"2021","unstructured":"Ou, X. et al. CRISPR\/Cas9 gene-editing in cancer immunotherapy: promoting the present revolution in cancer therapy and exploring more. Front. Cell Dev. Biol. 9, 674467 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2326_CR496","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01738-6","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol. Cancer 22, 35 (2023).","journal-title":"Mol. Cancer"},{"key":"2326_CR497","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","volume":"38","author":"DN Nguyen","year":"2020","unstructured":"Nguyen, D. N. et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat. Biotechnol. 38, 44\u201349 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2326_CR498","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1164\/rccm.202301-0181OC","volume":"208","author":"CN Chen","year":"2023","unstructured":"Chen, C. N. et al. Restoration of Foxp3(+) regulatory T Cells by HDAC-dependent epigenetic modulation plays a pivotal role in resolving pulmonary arterial hypertension pathology. Am. J. Respir. Crit. Care Med. 208, 879\u2013895 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2326_CR499","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2174\/1381612829666230901143203","volume":"29","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Involvement of CHRNA6 in the immune response in lung squamous cell carcinoma and its potential as a drug target for the disease. Curr. Pharm. Des. 29, 2091\u20132100 (2023).","journal-title":"Curr. Pharm. Des."},{"key":"2326_CR500","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13\u201325 (2013).","journal-title":"Immunity"},{"key":"2326_CR501","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich, J. Y. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann. Rheum. Dis. 81, 1685\u20131694 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2326_CR502","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002139","volume":"13","author":"JA Todd","year":"2016","unstructured":"Todd, J. A. et al. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med. 13, e1002139 (2016).","journal-title":"PLoS Med."},{"key":"2326_CR503","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12876-024-03176-0","volume":"24","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. The effects of low-dose IL-2 on Th17\/Treg cell imbalance in primary biliary cholangitis mouse models. BMC Gastroenterol. 24, 87 (2024).","journal-title":"BMC Gastroenterol."},{"key":"2326_CR504","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2023.03.230","volume":"165","author":"JR Allegretti","year":"2023","unstructured":"Allegretti, J. R. et al. Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology 165, 492\u2013495. e492 (2023).","journal-title":"Gastroenterology"},{"key":"2326_CR505","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08830185.2023.2274574","volume":"43","author":"R Zhang","year":"2024","unstructured":"Zhang, R. et al. Low-dose IL-2 therapy in autoimmune diseases: an update review. Int. Rev. Immunol. 43, 113\u2013137 (2024).","journal-title":"Int. Rev. Immunol."},{"key":"2326_CR506","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320916014","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Ther. Adv. Chronic Dis. 11, 2040622320916014 (2020).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"2326_CR507","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/TP.0000000000004866","volume":"108","author":"L Amini","year":"2024","unstructured":"Amini, L., Kaeda, J., Weber, O. & Reinke, P. Low-dose interleukin-2 therapy: fine-tuning Treg in solid organ transplantation?. Transplantation 108, 1492\u20131508 (2024).","journal-title":"Transplantation"},{"key":"2326_CR508","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","volume":"9","author":"SE Bentebibel","year":"2019","unstructured":"Bentebibel, S. E. et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rbetagamma-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 9, 711\u2013721 (2019).","journal-title":"Cancer Discov."},{"key":"2326_CR509","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14471-1","volume":"11","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat. Commun. 11, 661 (2020).","journal-title":"Nat. Commun."},{"key":"2326_CR510","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111478","volume":"41","author":"D VanDyke","year":"2022","unstructured":"VanDyke, D. et al. Engineered human cytokine\/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 41, 111478 (2022).","journal-title":"Cell Rep."},{"key":"2326_CR511","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31130-9","volume":"13","author":"S de Picciotto","year":"2022","unstructured":"de Picciotto, S. et al. Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein. Nat. Commun. 13, 3866 (2022).","journal-title":"Nat. Commun."},{"key":"2326_CR512","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jbm.a.37442","volume":"111","author":"GP Marshall","year":"2023","unstructured":"Marshall, G. P. et al. Biomaterials-based nanoparticles conjugated to regulatory T cells provide a modular system for localized delivery of pharmacotherapeutic agents. J. Biomed. Mater. Res. A 111, 185\u2013197 (2023).","journal-title":"J. Biomed. Mater. Res. A"},{"key":"2326_CR513","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103125","volume":"140","author":"TK Kishimoto","year":"2023","unstructured":"Kishimoto, T. K. et al. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease. J. Autoimmun. 140, 103125 (2023).","journal-title":"J. Autoimmun."},{"key":"2326_CR514","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202107373","volume":"18","author":"J Oh","year":"2022","unstructured":"Oh, J. et al. The effect of the nanoparticle shape on T cell activation. Small 18, e2107373 (2022).","journal-title":"Small"},{"key":"2326_CR515","doi-asserted-by":"publisher","first-page":"1291724","DOI":"10.3389\/fmicb.2023.1291724","volume":"14","author":"K Prame Kumar","year":"2023","unstructured":"Prame Kumar, K., Ooi, J. D. & Goldberg, R. The interplay between the microbiota, diet and T regulatory cells in the preservation of the gut barrier in inflammatory bowel disease. Front. Microbiol. 14, 1291724 (2023).","journal-title":"Front. Microbiol."},{"key":"2326_CR516","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02675-9","volume":"19","author":"SH Su","year":"2022","unstructured":"Su, S. H. et al. Fecal microbiota transplantation and replenishment of short-chain fatty acids protect against chronic cerebral hypoperfusion-induced colonic dysfunction by regulating gut microbiota, differentiation of Th17 cells, and mitochondrial energy metabolism. J. Neuroinflammation 19, 313 (2022).","journal-title":"J. Neuroinflammation"},{"key":"2326_CR517","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02539-x","volume":"18","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation. J. Transl. Med. 18, 382 (2020).","journal-title":"J. Transl. Med."},{"key":"2326_CR518","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3389\/fimmu.2020.00752","volume":"11","author":"T Hou","year":"2020","unstructured":"Hou, T. et al. IL-37 ameliorating allergic inflammation in atopic dermatitis through regulating microbiota and AMPK-mTOR signaling pathway-modulated autophagy mechanism. Front. Immunol. 11, 752 (2020).","journal-title":"Front. Immunol."},{"key":"2326_CR519","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.immuni.2018.12.015","volume":"50","author":"GJ Britton","year":"2019","unstructured":"Britton, G. J. et al. Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RORgammat(+) regulatory T cells and exacerbate colitis in mice. Immunity 50, 212\u2013224.e214 (2019).","journal-title":"Immunity"},{"key":"2326_CR520","doi-asserted-by":"publisher","first-page":"803101","DOI":"10.3389\/fimmu.2021.803101","volume":"12","author":"P Chen","year":"2021","unstructured":"Chen, P. & Tang, X. Gut microbiota as regulators of Th17\/Treg balance in patients with myasthenia gravis. Front. Immunol. 12, 803101 (2021).","journal-title":"Front. Immunol."},{"key":"2326_CR521","doi-asserted-by":"publisher","first-page":"1341032","DOI":"10.3389\/fcimb.2024.1341032","volume":"14","author":"L Li","year":"2024","unstructured":"Li, L. et al. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the \u201clung and large intestine stand in exterior-interior relationship\u201d theory. Front. Cell. Infect. Microbiol. 14, 1341032 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2326_CR522","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"2326_CR523","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118 (2017).","journal-title":"Cell Res."},{"key":"2326_CR524","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139\u2013148 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2326_CR525","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41590-023-01645-4","volume":"24","author":"A Schnell","year":"2023","unstructured":"Schnell, A. et al. Targeting PGLYRP1 promotes antitumor immunity while inhibiting autoimmune neuroinflammation. Nat. Immunol. 24, 1908\u20131920 (2023).","journal-title":"Nat. Immunol."},{"key":"2326_CR526","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"ZW Lai","year":"2018","unstructured":"Lai, Z. W. et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet 391, 1186\u20131196 (2018).","journal-title":"Lancet"},{"key":"2326_CR527","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.kint.2016.09.022","volume":"91","author":"JJ Yan","year":"2017","unstructured":"Yan, J. J. et al. IL-2\/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4 CD25 Foxp3 regulatory T cells. Kidney Int. 91, 603\u2013615 (2017).","journal-title":"Kidney Int."},{"key":"2326_CR528","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.immuni.2018.07.015","volume":"49","author":"JD Proto","year":"2018","unstructured":"Proto, J. D. et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity 49, 666\u2013667.e666 (2018).","journal-title":"Immunity"},{"key":"2326_CR529","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka, A. & Sakaguchi, S. Targeting Treg cells in cancer immunotherapy. Eur. J. Immunol. 49, 1140\u20131146 (2019).","journal-title":"Eur. J. Immunol."},{"key":"2326_CR530","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez, R., Poder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614\u2013628 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2326_CR531","doi-asserted-by":"crossref","unstructured":"Cinier, J. et al. Recruitment and expansion of Tregs cells in the tumor environment\u2014how to target them? Cancers 13, 1850 (2021).","DOI":"10.3390\/cancers13081850"},{"key":"2326_CR532","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.trecan.2017.06.005","volume":"3","author":"HP Wang","year":"2017","unstructured":"Wang, H. P., Franco, F. & Ho, P. C. Metabolic regulation of Tregs in cancer: opportunities for immunotherapy. Trends Cancer 3, 583\u2013592 (2017).","journal-title":"Trends Cancer"},{"key":"2326_CR533","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.immuni.2019.06.017","volume":"51","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8 T cell-derived interferon-\u03b3. Immunity 51, 381\u2013397.e386 (2019).","journal-title":"Immunity"},{"key":"2326_CR534","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/nyas.13625","volume":"1417","author":"K Shitara","year":"2018","unstructured":"Shitara, K. & Nishikawa, H. Regulatory T cells: a potential target in cancer immunotherapy. Ann. N.Y. Acad. Sci. 1417, 104\u2013115 (2018).","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2326_CR535","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26352-2","volume":"12","author":"A Lain\u00e9","year":"2021","unstructured":"Lain\u00e9, A. et al. Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation. Nat. Commun. 12, 6228 (2021).","journal-title":"Nat. Commun."},{"key":"2326_CR536","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531\u2013564 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"2326_CR537","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1309\/AJCP6VDBL4BRXRQA","volume":"137","author":"HJ Meyerson","year":"2012","unstructured":"Meyerson, H. J. et al. NRP-1\/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia. Am. J. Clin. Pathol. 137, 39\u201350 (2012).","journal-title":"Am. J. Clin. Pathol."},{"key":"2326_CR538","doi-asserted-by":"crossref","unstructured":"Adamczyk, M. et al. The expression of activation markers CD25 and CD69 increases during biologic treatment of psoriasis. J. Clin. Med. 12, 6573 (2023).","DOI":"10.3390\/jcm12206573"},{"key":"2326_CR539","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1083\/jcb.109.5.2463","volume":"109","author":"JS Geoffroy","year":"1989","unstructured":"Geoffroy, J. S. & Rosen, S. D. Demonstration that a lectin-like receptor (gp90MEL) directly mediates adhesion of lymphocytes to high endothelial venules of lymph nodes. J. Cell Biol. 109, 2463\u20132469 (1989).","journal-title":"J. Cell Biol."},{"key":"2326_CR540","doi-asserted-by":"publisher","first-page":"13330","DOI":"10.1073\/pnas.1510045112","volume":"112","author":"M Schmaler","year":"2015","unstructured":"Schmaler, M. et al. IL-7R signaling in regulatory T cells maintains peripheral and allograft tolerance in mice. Proc. Natl. Acad. Sci. USA 112, 13330\u201313335 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2326_CR541","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21563-z","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Structures of mouse and human GITR-GITRL complexes reveal unique TNF superfamily interactions. Nat. Commun. 12, 1378 (2021).","journal-title":"Nat. Commun."},{"key":"2326_CR542","doi-asserted-by":"crossref","unstructured":"Godfrey, J. et al. TIGIT is a key inhibitory checkpoint receptor in lymphoma. J. Immunother. Cancer. 11, e006582 (2023).","DOI":"10.1136\/jitc-2022-006582"},{"key":"2326_CR543","doi-asserted-by":"crossref","unstructured":"Chiang, E. Y. & Mellman, I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother. Cancer. 10, 104\u2013115 (2022).","DOI":"10.1136\/jitc-2022-004711"},{"key":"2326_CR544","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00011-023-01808-x","volume":"72","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z., Guo, J. & Jia, R. Treg plasticity and human diseases. Inflamm. Res. 72, 2181\u20132197 (2023).","journal-title":"Inflamm. Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02326-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:03:59Z","timestamp":1760461439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02326-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":544,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2326"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02326-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}